



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Improved medication communication and patient involvement at care transitions (IMPACT-care): study protocol for a pre-post intervention trial in older hospitalised patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2025-099547
Article Type:	Protocol
Date Submitted by the Author:	20-Jan-2025
Complete List of Authors:	Cam, Henrik; Uppsala University, Department of Pharmacy Franzon, Kristin; Uppsala University, Department of Public Health and Caring Sciences Östman, Victoria; Uppsala University, Department of Pharmacy Kälvemark Sporrang, Sofia; Uppsala University, Department of Pharmacy Kempen, Thomas Gerardus Hendrik; Uppsala University, Department of Pharmacy; Utrecht University, Utrecht Institute for Pharmaceutical Sciences Nielsen, Elisabet I; Uppsala University, Department of Pharmacy Lindner, Karl-Johan; Region Västmanland, Department of Pharmacy Ekelo, Beatrice; Region Västmanland, Department of Pharmacy Bernsten, Cecilia; Uppsala University, Department of Pharmacy Ehlin, Ulf; Östhammar Association of Relatives and Elderly People Lindmark, Stina; Uppsala University Hospital, Geriatrics Hadziosmanovic, Nermin; Uppsala Clinical Research Center Gillespie, Ulrika; Uppsala University, Department of Pharmacy
Keywords:	Clinical Protocols, Health Services for the Aged, Hospital to Home Transition, Medication Adherence, Patient-Centered Care, Pharmacists

SCHOLARONE™
Manuscripts

TITLE

Improved medication communication and patient involvement at care transitions (IMPACT-care): study protocol for a pre-post intervention trial in older hospitalised patients

AUTHOR NAMES AND AFFILIATIONS

Henrik Cam (henrik.cam@uu.se)^a, Kristin Franzon (kristin.franzon@uu.se)^b, Victoria Östman (victoria.ostman@uu.se)^a, Sofia Källemark Sporrang (sofia.kallemark-sporrang@uu.se)^a, Thomas Gerardus Hendrik Kempen (thomas.kempen@uu.se)^{a,c}, Elisabet I Nielsen (elisabet.nielsen@uu.se)^a, Karl-Johan Lindner (karl.johan.lindner@regionvastmanland.se)^d, Beatrice Ekelo (beatrice.ekelo@regionvastmanland.se)^d, Cecilia Bernsten (cecilia.bernsten@klotblix.se)^a, Ulf Ehlin (ulf.ehlin@telia.com)^e, Stina Lindmark (stina.lindmark@yahoo.se)^f, Nermin Hadziosmanovic^g (Nermin.Hadziosmanovic@ucr.uu.se), Ulrika Gillespie (ulrika.gillespie@akademiska.se)^a

^a Department of Pharmacy, Uppsala University, Uppsala, Sweden

^b Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

^c Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

^d Department of Pharmacy, Region Västmanland, Västerås, Sweden

^e Östhammar Association of Relatives and Elderly People, Östhammar, Sweden

^f Geriatrics, Uppsala University Hospital, Uppsala, Sweden

^g Uppsala Clinical Research center, Uppsala, Sweden

Corresponding author:

Henrik Cam

Email: henrik.cam@farmaci.uu.se

ABSTRACT

Introduction

Care transitions, particularly hospital discharge, present significant risks to patient safety. Deficient medication-related discharge communication is a major contributor, posing a substantial risk of harm to older patients. This protocol outlines the Improved Medication Communication and Patient Involvement at Care Transitions (IMPACT-care) intervention study, designed to evaluate the effects of a multi-faceted intervention for older hospitalised patients on medication-related discharge communication compared to usual hospital care.

Methods and analysis

A pre-post intervention study will be conducted in two surgical and one geriatric ward of a university hospital in Sweden. The study will begin with a control period delivering care as usual, followed by a training period and then an intervention period. The intervention comprises four components performed by clinical pharmacists: (1) an information package provided to patients and/or their informal caregivers, (2) preparation of medication-related discharge documentation, (3) facilitation of discharge communication, and (4) a follow-up call to patients or their informal caregiver. Eligible participants are aged ≥ 65 years, manage their own medications independently or with informal caregiver support, and are admitted to the study wards. Both study periods (control and intervention) will last until a total of 115 patients have been included in each period. The primary outcome is the quality of medication-related discharge documentation, assessed using the Complete Medication Documentation at Discharge Measure (CMDD-M). Secondary outcomes include patients' perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management, adherence to medication changes from hospitalisation that persist after discharge, and unplanned healthcare visits following discharge. A process evaluation is planned to explore how the intervention was implemented. Patient inclusion began in September 2024.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Ethics and dissemination

The study protocol has been approved by the Swedish Ethical Review Authority (registration no.: 2023-03518-01 and 2024-04079-02). Results will be published in open-access international peer-reviewed journals, and presented at national and international conferences.

52

53

Trial registration number

NCT06610214

54

STRENGTHS AND LIMITATIONS OF THIS STUDY

- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- Uses a comprehensive, multi-faceted intervention designed to address gaps in medication communication both during hospitalisation and after discharge.
- Conducted in both non-surgical and surgical wards, increasing the generalisability of findings to other healthcare settings.
- The inclusion of a process evaluation provides insights into the implementation and adherence to intervention components, offering valuable information to understand and interpret the study findings.
- The pre-post design without randomisation limits the ability to establish causal relationships between intervention and observed outcomes.
- Due to the complex, multi-faceted nature of the intervention, it is not possible to determine which specific intervention components contribute most to the observed effects.

66

MAIN TEXT

67

INTRODUCTION

68

69

70

71

The ageing population is rapidly increasing, with individuals aged 65 and older expected to rise from 10% in 2022 to 16% by 2050 [1]. Older adults frequently experience multiple chronic conditions, making them twice as likely to require hospital care compared to younger adults [2]. Medications are a primary treatment for many health conditions, and as the prevalence of multiple illnesses

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

increases, so does the use of medications, increasing the risk of medication-related complications [3,4]. One in six hospital admissions and one in five readmissions among older patients are medication-related [5,6], most of which are preventable [7]. Care transitions, particularly hospital discharges, pose significant risks to patient safety and is highlighted by the World Health Organization (WHO) as a focus for healthcare improvements [8]. More than one-third of older patients experience adverse drug reactions within eight weeks post-discharge [9], often attributed to poor communication and coordination between hospitals, subsequent healthcare providers, and patients or their informal caregivers [6,10–13]. Most hospitalised older patients experience changes to their medication regimens, which persist after discharge and should be effectively communicated to all individuals involved in their care [14,15].

Relying on written discharge notes and referrals to bridge communication gaps regarding medication changes and follow-up plans has proven unreliable, as this information is often delivered late or of insufficient quality [16–19]. Discharge consultations often lack structure and patient-centeredness, frequently being treated as a checklist item for healthcare professionals (HCPs) to complete before discharge [20–22]. Physicians tend to adopt an authoritative role in medication discussions, which can discourage older patients from actively participating in their medication management [23]. To foster patient involvement, HCPs should act as advocates rather than paternalistic figures [24]. Patient-centred communication at discharge is essential for equipping patients with the knowledge and confidence to manage their medications and self-care [20]. Involving patients in medical decisions is a key component of patient-centred care, leading to improved patient satisfaction and clinical outcomes, such as better glycaemic and blood pressure control [25,26]. However, older patients may be less inclined or unable to participate actively, often due to factors such as cognitive or physical impairments [27]. Many feel insufficiently empowered to engage in discussions about their medications and tend to rely on HCPs, following prescriptions without question [22,28]. Even when discharge information is presented in a structured format, older patients frequently struggle to retain details about their medications [29]. Informal caregivers

1
2
3 98 can be vital in supporting patient involvement and bridging communication gaps between HCPs and
4
5 99 older patients [12,23].
6

7
8 100 To address these issues, the research project Improved Medication Communication and
9
10 101 Patient Involvement at Care Transitions (IMPACT-care) was initiated [30]. The project began with
11
12 102 exploratory studies of the discharge communication [12,19,22], ultimately leading to the
13
14 103 development of the intervention presented in this protocol.
15

16 104 **Aims and objectives**

17
18
19 105 The overall aim is to evaluate the effects of a multi-faceted intervention on improving medication-
20
21 106 related discharge communication for older hospitalised patients, compared to usual hospital care.
22

23 107 The primary objective is to assess the intervention’s impact on the quality of written
24
25 108 medication-related discharge documentation compared to usual hospital care. Secondary objectives
26
27 109 include evaluating the intervention's effect on patients' perceived involvement in discharge
28
29 110 medication communication and their confidence in post-discharge medication management, as well
30
31 111 as adherence to medication changes from hospitalisation that persist after discharge, and the need
32
33 112 for unplanned healthcare visits following discharge, all in comparison to usual hospital care.
34
35
36


37 113 **METHODS AND ANALYSIS**

38
39
40 114 This protocol was developed and reported in accordance with the Standard protocol items:
41
42 115 recommendations for interventional trials (SPIRIT) 2013 statement [31], the SPIRIT-outcomes 2022
43
44 116 extension [32], and the Template for intervention description and replication (TIDieR) checklist [33].
45
46

47 117 **Study design**

48
49 118 This prospective intervention study uses a pre-post design (Figure 1). Control patients will be
50
51 119 enrolled first (control period), followed by a training phase during which HCPs in the study wards will
52
53 120 be trained to implement the intervention. Once the HCPs are considered sufficiently trained, the
54
55 121 intervention period will start. Enrolment during both the control and intervention period will stop
56
57 122 once the target sample size is reached, with patient follow-up continuing for four months post-
58
59
60

discharge. Based on the pilot study, the control and intervention periods are each expected to last approximately six months, and the training phase will last around two months. Figure 1 provides a schematic overview of the study design. Study enrolment began in September 2024 (control group).



^α CMDD-M, a point-based instrument using data from the patient's electronic health records.

^β PIMCH-Q, a questionnaire to patients measuring their perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management.

^γ Data on lasting medication changes from the patient's electronic health records are compared to pharmacy dispensing data collected 120 days post-discharge.

^δ Unplanned hospital revisits and medication-related readmissions up to 90 days post-discharge.

CMDD-M = complete medication documentation at discharge measure, HCPs = healthcare professionals, IMPACT-care = improved medication communication and patient involvement at care transitions, PIMCH-Q = patient involvement in medication communication at hospital discharge questionnaire

Figure 1. Schematic overview of the study design.

Rationale for study design

A randomised trial was deemed infeasible - neither at the patient level, due to contamination risks, nor at the ward level or as a stepped-wedge design, as these would require a large number of wards and exceed available resources. Consequently, a pre-post study design was selected, complemented by an interrupted time series (ITS) analysis for exploratory purposes. The ITS analysis, analysing data at regular intervals both before and after the intervention, allows for a more nuanced interpretation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

143 of the primary results by accounting for potential seasonal variations and changes in effect over
144 time.
145 Settings
146 The study is conducted in two surgical wards and one geriatric ward at Uppsala University Hospital in
147 Sweden. Surgical wards mainly handle emergency surgeries, as well as liver-pancreas,
148 transplantation, oesophagus-stomach, endocrine, and colorectal surgeries. The geriatric ward treats
149 older patients with complex acute medical and rehabilitation needs. These two clinical specialties
150 were selected to assess whether the intervention could have an effect across various clinical
151 settings.
152 Study population and recruitment
153 Patients aged 65 years or older, who manage their own medications either independently or with
154 support from an informal caregiver, and are admitted to the study wards, are eligible for inclusion.
155 An informal caregiver is defined as an unpaid individual, often a family member, who assists the
156 patient with daily activities, healthcare communication, and medication management. Exclusion
157 criteria apply if patients meet any of the pre-determined conditions that would hinder the successful
158 delivery of the intervention or the reliable collection of outcome data (a detailed list is provided in
159 Table 1).
160 The researchers, who are employed by the hospital, screen the admission lists of the study
161 wards daily on weekdays to identify eligible patients, who are then asked for inclusion by the
162 researchers or clinical pharmacists on the ward. Eligibility is primarily determined through the
163 patient’s electronic health records (EHR), with any uncertainties resolved through discussions with
164 HCPs at the study wards. Once identified, patients are informed both verbally and in writing, and
165 written informed consent is requested. Patients meeting exclusion criteria 10-15 in Table 1 are
166 excluded at discharge.

During the recruitment of control patients, all patients fulfilling the inclusion and exclusion criteria are invited to participate. During the intervention period, patient inclusion is determined based on the capacity of the pharmacists performing the intervention. The pharmacists' capacity will be evaluated through regular feedback discussions, ensuring that the inclusion process aligns with their workload. If the number of eligible patients exceeds the pharmacists' capacity, the pharmacist, in collaboration with the research team, will determine how many eligible patients can be included. To prioritise which patients to include, a random priority number will be generated for each eligible patient at the study ward level using Microsoft Excel, with those assigned the highest priority included first.

Table 1. The inclusion and exclusion criteria in the study. Patients meeting exclusion criteria 1-9 are excluded at the time of hospital admission, while those meeting exclusion criteria 10-15 are excluded at the time of discharge.

Inclusion criteria	
1.	65 years or older.
2.	Manages their own medications, either independently or with support from an informal caregiver, prior to inclusion.
Exclusion criteria	
Checked at hospital admission	
1.	Registered in a region outside the study hospital (limited data availability).
2.	Admitted from a nursing home (no own medication management prior to admission).
3.	Unable to receive information or provide consent independently (due to cognitive impairment or unresponsiveness).
4.	Already included in the study.
5.	Patient delocalised to the study ward with another medical discipline responsible for the patient's care (formally, no study ward patient).
6.	In a late palliative phase prior to inclusion (intervention not suitable).
7.	Unable to communicate in Swedish (hindering intervention delivery).
8.	Has restricted personal information in the EHR (limited data availability).
9.	Admitted for transplantation (intervention not suitable).
Checked at hospital discharge	
10.	Discharged to a nursing home (intervention not suitable).
11.	Patient transitions to late palliative phase during the hospitalisation (intervention not suitable).
12.	Patient is transferred to a non-study ward and is discharged from there (hindering intervention delivery).
13.	The patient dies during the course of the hospital stay (hindering intervention delivery).

14. No medication changes that last post-discharge during the hospitalisation (intervention not suitable).

15. The duration of stay on the study ward is less than 48 working hours (excluding time from 4:00 PM before weekends/public holiday to 8:00 AM the day after a weekend/public holiday) (hindering intervention delivery).

EHR = electronic health records

Intervention development

The intervention aims to improve medication communication during the discharge process for older patients. It was designed by a team of researchers, HCPs, and representatives of patients and informal caregivers, building on findings from previous research conducted by our group [12,19,34]. The inclusion rate, as well as the feasibility of selected intervention components and outcome measures, were tested in unpublished pilot studies conducted at geriatric and surgical wards at Uppsala University Hospital, Sweden. These studies involved a total of 106 patients between September 2023 and May 2024 (Nordin J, Berlin K, Sabouni Y, du Thinh C, *et al.*: Facilitating patient empowerment at hospital discharge: A pilot study testing the feasibility of the IMPACT-care intervention, unpublished). Based on the results of these pilot studies, the intervention and study design were refined before advancing to the main trial.

Control period (preintervention)

During the control period, care as usual will be provided at the study wards. Clinical pharmacists are part of the care team at the wards and primarily assist with medication reviews at patient admission and discharge but are not routinely involved in the discharge communication process. At hospital admission, medication reconciliation is conducted by either a pharmacist or a physician. If needed, a medication review is carried out by the physician, with or without support from a pharmacist. Any changes to the patients' medication lists are made by wards physicians or nurse practitioners (specialised nurses at the surgical wards). Oral medication-related communication with the patient and/or informal caregiver, is typically handled by nurses, physicians, and pharmacists during patient consultations. At discharge, hospitals are required to provide a discharge summary to the next

healthcare provider(s) and a discharge letter intended for the patient [35,36]. Both documents are typically prepared by ward physicians and include details about the hospitalisation, medication changes (along with the rationales for those), planned treatment duration, and follow-up plans. The discharge letter, however, is expected to be written in layman's language. In some cases, these discharge documents are written by a physician who has not met the patient prior to discharge. Pharmacists sporadically assist in preparing these discharge documents, but not in a standardised manner. Additionally, it is standard practice for ward physicians to send specific referrals to the next healthcare provider(s), outlining follow-up requests related to medication changes. In addition, ward physicians conduct an oral discharge consultation, during which the patient is informed about the medication changes and follow-up plans before discharge.

While patients receive written information materials with practical information about the wards and surgical procedures at admission, no materials specifically address medications or medication communication at discharge. Inviting informal caregivers to participate in discharge consultations and HCPs conducting follow-up calls after discharge occurs in selected cases but is not routine practice.

Implementation period: training of HCPs

The training period will last approximately two months between the control and intervention phases. During this period, HCPs - primarily physicians and pharmacists on the study wards - will undergo training. Training of physicians will focus mainly on the importance of writing discharge documentation and effectively utilising pharmacist support for this process. Training of pharmacists, on the other hand, will focus on implementing the intervention components and understanding the principles of person-centred medication communication at discharge. The training will be delivered through multiple sessions led by the researchers, addressing how the study may impact daily ward processes and how to integrate the intervention components into existing practices. To accommodate new HCPs hired during the study period or those unable to attend the live sessions, digital training materials will be developed to ensure that all necessary training can be completed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

227 Additionally, the pharmacists, who play a central role in delivering the intervention components, will
228 receive a standardised operation procedure document. Other HCPs on the wards, excluding
229 physicians and pharmacists, will be informed about the study through meetings and information
230 emails, which will outline how they may be affected by the study. For training purposes, selected
231 patients will undergo the intervention components without being included in the study. Additionally,
232 one of the researchers will also regularly visit the study wards to support the HCPs in implementing
233 the intervention components during this phase.

234 **Intervention period**

235 The intervention is designed to be implemented on hospital wards by clinical pharmacists who are
236 already part of the patient care team. Each of the study wards in our study has a full-time equivalent
237 clinical pharmacist present during weekday office hours, with a continuous presence established
238 over the past 15 years before the study began. The pharmacists involved have varying levels of
239 experience, from limited to more extensive, some of whom have a one-year full-time postgraduate
240 MSc in clinical pharmacy. All relevant details about the completed intervention components and any
241 other actions taken by the pharmacist will be documented as usual in the patient’s EHR. The
242 IMPACT-care intervention consists of the following four components (Figure 2):

- 243 1. *Information package provided to patients and/or informal caregivers.*
244 In our pre-study [22], it was identified that medication-related discharge communication is not
245 tailored to support patients’ self-care needs post-discharge. Additionally, patients were unprepared
246 for medication-related consultations prior to discharge. To address these challenges, the research
247 team, inspired by a similar intervention component developed in the UK [37], designed an
248 information package consisting of a patient booklet (Supplementary material I) and a 3-minute
249 supplementary video, with input from clinical pharmacists at Uppsala university hospital and a panel
250 of public representatives.

251 The booklet is designed to inform, prepare, and engage patients and/or their informal
252 caregiver in medication communication at discharge and self-care after returning home. It is

organised into four sections: 1. Hospitalisation course, 2. Medications, 3. Discharge, and 4. Advice on self-care. The first two sections feature a question prompt list [38], a set of discussion points intended to guide conversations with HCPs and encourage patients to actively participate in their care. The use of questions prompt list has been found to enhance patient participation in medication-related communication [39,40]. The third section contains a checklist of essential points for patients to review with HCPs to help confirm they have sufficient knowledge before leaving the hospital. The final section provides practical advice on seeking medication and general healthcare support after returning home.

The supplementary video highlights the importance of patient engagement in their own care and demonstrates how to use the booklet effectively as a supporting tool. Patients will receive the booklet in printed format at admission to the study ward, and the video will be shown bedside on a tablet. These materials will be accompanied by an oral consultation with a pharmacist, who will explain the content and guide the patient on how to use the booklet effectively. Both the booklet and video will also be available online. If the patient wishes, the pharmacist will provide the patient's informal caregiver access to the information package. This can be done in person if the caregiver is present at the ward or remotely via phone, guiding them on how to access the materials online.

2. Preparation of medication-related discharge documentation.

Incompleteness and poor quality of medication-related discharge communication from hospitals is a common problem [41,42], making it difficult for subsequent HCPs to trust this information [12,17,43]. Pharmacist involvement can significantly improve the completeness and quality of such communication [41,42]. Consequently, in our study, the pharmacist will review relevant parts of the patient's EHR and medication list prior to discharge to identify any lasting medication changes made during the hospitalisation. The pharmacist will collaborate with the discharging physician to reconcile follow-up plans for these changes. All medication changes, including reasons for the adjustments (when known), planned treatment duration, follow-up plans, and the ward's phone number for any post-discharge inquiries from the patient, will be documented in a standardised

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

manner in the EHR by the pharmacist. This documentation will form the basis for detailing medication changes and follow-up plans in the patient’s discharge letter and the discharge summary intended for the next healthcare provider, both of which are written by a ward physician.

3. *Facilitation of discharge communication.*

To increase the likelihood that patients and their informal caregiver remember and use the booklet provided to them during intervention component 1, the pharmacist will consult the patient as the discharge date approaches. The consultation will include a review of the booklet’s content and a reminder to use it. If the patient wishes, the pharmacist will also contact the patient’s informal caregiver, either by phone or face-to-face, depending on the situation, to review the booklet and remind them to use it.


Informal caregivers are considered as valuable support in helping patients recall information and manage self-care after returning home [12]. However, they are often involved in a limited way in medication-related discharge communication by HCPs [22,44]. To address this gap, the pharmacist in our study will arrange for an informal caregiver to attend the discharge consultation with the physician, if the patient so wishes. The pharmacist will contact the informal caregiver by phone once the discharge date is confirmed - no later than the morning of discharge - and invite them to participate in the consultation. Participation can be in person, by phone, or via video call depending on their availability. The pharmacist will then inform the discharging physician that the patient has requested their informal caregiver’s involvement in the discharge consultation.

4. *Follow-up call to patients or their informal caregiver.*

The timing of medication-related discharge communication often occurs at a suboptimal moment for patients, making it difficult for them to retain and recall the information after returning home [22]. Incorporating intervention components both during hospitalisation and after discharge can help support medication continuity in older patients and bridge transitions [45]. Telephone follow-ups, in particular, have shown promise in enhancing this support [45]. Therefore, in our study, patients or their informal caregiver (based on the patient’s preference) will be offered a follow-up call with a

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

clinical pharmacist post-discharge. If requested, the appointment for this call will be scheduled in consultation with the patient/informal caregiver, between 3-7 days after discharge, depending on the patient's availability. The pharmacist will then contact the patient/informal caregiver at the agreed time. During the call, the pharmacist will start by addressing any questions the patient/informal caregiver may have, providing direct answers or referring inquiries to the appropriate HCP as needed. Following this, the pharmacist will review the medication-related discharge information, focusing on the updated medication list and details outlined in the discharge letter, including medication changes, reasons for the adjustments, planned treatment duration, and follow-up plans. Additionally, the pharmacist will remind the patient of the advice on when and how to seek care, as presented in the booklet provided during intervention component 1.



* Based on the patient's preference, this may include their informal caregiver.

IMPACT-care = improved medication communication and patient involvement at care transitions

Figure 2. Overview of the IMPACT-care intervention, comprising four intervention components implemented during patient hospitalisation and post-discharge.

Outcomes

All outcomes will be assessed for participants from both the control and the intervention group (Table 2).

Primary outcome

The improvement in the quality of medication-related discharge documentation will be the primary outcome, assessed using the average score from the Complete Medication Documentation at Discharge Measure (CMDD-M) (Supplementary material II). This point-based instrument, ranging from 0 to 9 points, is based on Swedish legislation [36] outlining the requirements for written medication-related discharge documentation. The CMDD-M comprises five items, each scored from 0-1 or 0-2 points depending on the criteria. It evaluates the completeness and quality of medication-

1
2
3 330 related discharge documents for individual hospital discharges, including the patient’s discharge
4
5 331 letter, the discharge summary intended for the next healthcare provider, and the presence of a
6
7 332 follow-up request to bridge the gaps post-discharge. Improving the quality of discharge
8
9
10 333 documentation is critical for ensuring continuity of care and patient safety during transitions of care
11
12 334 [17]. Poor-quality documentation has been associated with medication errors [11], non-adherence
13
14 335 [46], and avoidable need for medical care after discharge [47,48]. By focusing the primary outcome
15
16 336 on this domain, the trial aims to address an important gap in care that impacts patient outcomes.

17
18
19 337 *Secondary outcomes*

- 20
21 338 • The proportion of patients with complete medication-related discharge documentation. This
22
23 339 will be assessed using the CMDD-M to determine the prevalence of patients achieving the
24
25 340 maximum score of 9 points.
- 26
27 341 • Improvement in patients' perceptions of involvement in discharge medication communication
28
29 342 and their confidence in post-discharge medication management. This will be assessed by the
30
31 343 average score by the Patient Involvement in Medication Communication at Hospital discharge
32
33 344 Questionnaire (PIMCH-Q) (Supplementary material III). It consists of eight statements rated on a
34
35 345 four-point Likert scale. It is designed with three dimensions: perception of knowledge,
36
37 346 participation, and confidence, and aims to measure patients' perceived involvement in
38
39 347 medication communication during hospitalisation and their confidence in managing
40
41 348 medications after discharge. The questionnaire will be sent to patients one week post-
42
43 349 discharge.
- 44
45 350 • Adherence to medication changes made during hospitalisation that persist post-discharge. This
46
47 351 will be assessed by measuring the number of instances of non-adherence. Non-adherence to a
48
49 352 medication change is defined as follows:
50
51
52
53
54 353 a. New or modified medications: A medication initiated or modified during
55
56 354 hospitalisation (i.e., changes in strength, dose, or formulation) that is not dispensed
57
58 355 from a community pharmacy within 14 days post-discharge This applies regardless
59
60

of whether the reason is a missing prescription or the patient not filling the prescription. Changes in strength or dose are included only when they create a safety risk for the patient if the previous prescription is used (e.g., reducing the dose of a tablet from 10 mg once daily to 2.5 mg once daily, which would require the patient to split the same tablet twice to get the correct dose, a practice considered unsafe).

- b. Discontinued medications: A medication discontinued during hospitalisation (or with altered strength or formulation) that is erroneously dispensed using a previous prescription within 120 days post-discharge.

The rationale for collecting data up to 120 days post-discharge is based on standard pharmacy practices in Sweden, where medications are typically dispensed for a 90-day (three-month) supply at a time. Patients may have leftover supplies of discontinued medications at home and continue using them. However, if these medications are not refilled at a pharmacy within 120 days, the patient is considered adherent to the discontinuation.

- The proportion of patients who are fully adherent to the medication changes made during hospitalisation that persist post-discharge. This will be assessed by determining the prevalence of patients who have no instances of non-adherence as described above.
- Unplanned healthcare visits post-discharge. This will be assessed using the following outcome measures:
 - The prevalence of patients with at least one unplanned hospital revisit (a composite measure of unplanned readmissions and emergency department visits) at 7, 30, and 90 days post-discharge.
 - The prevalence of patients with at least one unplanned readmission at 7, 30, and 90 days post-discharge.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- The prevalence of patients with at least one emergency department visit (not followed by admission) at 7, 30, and 90 days post-discharge.
- The time to the first unplanned hospital revisit within 90 days.
- The time to the first unplanned readmission within 90 days.
- The time to the first emergency department visit within 90 days.
- The prevalence of patients with at least one potentially medication-related hospital readmission at 7, 30, and 90 days post-discharge, assessed using the validated AT-HARM10 tool [49,50].

Table 2. Timeline and overview of the scheduled data collection for both the control and intervention group participants.

	Admission	Discharge	Follow-up				
Time points (day)	-1 ^α	0	7	14	30	90	120
Study inclusion							
Eligibility screening	x	x					
Informed consent	x						
Demographic data	x	x					
Outcome measures							
CMDD-M ^β		x					
PIMCH-Q ^γ			x				
Adherence to medication changes				x			x
Hospital revisits			x		x	x	
Hospital readmissions			x		x	x	

Emergency department visits			x		x	x	
Medication-related readmissions			x		x	x	

^α Time point at which the patient is admitted to the study ward.

^β CMDD-M, a point-based instrument using data from the patient's electronic health records.

^γ PIMCH-Q, a questionnaire to patients measuring their perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management.

CMDD-M = complete medication documentation at discharge measure, PIMCH-Q = patient involvement in medication communication at hospital discharge questionnaire

Data collection

Screening of patients at the study wards will be performed by the researchers, who are employed by the hospital. This will be done using information from the EHR and, if any unclarities occur, through contact with the ward HCPs. The researchers will invite eligible patients to participate and patients willing to participate will be asked to sign informed consent. Data will be collected from all participants, regardless of their adherence to the intervention, provided they do not withdraw their consent to participate in the study. This approach ensures complete follow-up data for inclusion in the intention-to-treat (ITT) analysis. The data collection will proceed in several steps (Table 2) and will be conducted by researchers in the research team and trained research assistants. To ensure uniformity of data collection, standard operating procedures have been developed. Data will be pseudonymised and transferred to case report forms (CRFs) in an electronic data capture system, REDCap [51]. All data processing and analysis will be based on the data in these CRFs and will be shared and discussed in pseudonymised form. Any forms and electronic files that reveal research data of an individual patient will be stored in a locked archive at the hospital pharmacy. Access to the final trial dataset will be restricted to the members of the research team.

Demographic data

Demographic data collected from the EHR will include age, gender, renal function, admission and discharge dates, medication treatment at admission and discharge, whether the patient has support by automatic dose-dispensation of medications, disease diagnoses, primary diagnosis for admission,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

home care support, whether the patient lives alone, and the number of emergency department visits and hospital admissions in the past year. Information about patients' education level will be gathered through the researchers asking the patients at inclusion.

Completeness and quality of discharge documentation

After patient discharge, the discharge letter, discharge summary, and referrals to next healthcare providers for follow up will be extracted from the EHR for scoring according to CMDD-M. Although the responsiveness of the CMDD-M has not yet been evaluated, the instrument was specifically developed to be used in clinical settings in Sweden. Initial validation demonstrated that the instrument is feasible for use in our setting. Inter-rater reliability was assessed using Cohen's weighted kappa with both linear (Kw linear) and quadratic (Kw quadratic) weights. The Kw linear for the comparison between two clinical pharmacists was 0.92, while the comparison between their consensus and a geriatrician yielded a Kw linear of 0.64. Similarly, the Kw quadratic was 0.97 for the comparison between the pharmacists and 0.80 for the comparison between their consensus and the geriatrician. These findings indicate moderate to almost perfect reliability between raters and suggest that the CMDD-M instrument provides robust reliability in assessing the quality and completeness of medication-related discharge documentation in older hospitalised patients (Bertilsson E, Cam H, Östman V, Franzon K, Gillespie U: Development and validation of an instrument to assess quality and completeness of medication-related discharge documentation, submitted for publication). Given its design and focus on aspects directly relevant to our intervention, we anticipate it to effectively capture meaningful changes within our study sample. To ensure objectivity, the assessment using the CMDD-M will be conducted by the researchers in a blinded manner. Data extracted from the EHR will be masked to prevent assessors from linking patients to specific time periods, ensuring they remain unaware whether the patient belongs to the control or intervention group.

Patients' experience

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

441 The PIMCH-Q will be sent to patients by mail or email, depending on their preferences, one week
442 after the discharge date. The patients are asked to answer the questionnaire as soon as possible. If
443 no response is received within 10 days, the research team will follow-up with a reminder via email or
444 phone. During the reminder call, patients will also be offered the option to respond by phone if
445 preferred. The PIMCH-Q was selected for this study because, to the best of our knowledge, no
446 existing instrument adequately captures medication-related patient experiences during hospital
447 discharge. While its responsiveness has not yet been validated, the tool was specifically designed to
448 assess patient involvement in medication communication and confidence in medication
449 management post-discharge, which are core aspects of this study. Despite the need for further
450 validation, the PIMCH-Q remains the most suitable tool for achieving our study objectives.

451 *Adherence to medication changes*

452 Data about the lasting medication changes made and prescribed during hospitalisation will be
453 gathered from the EHR. Information on medications dispensed from pharmacies for each patient
454 120 days post-discharge will be obtained from the Swedish National Board of Health and Welfare's
455 medication register. This register contains data on all medications dispensed from community
456 pharmacies in Sweden on a patient level. The extracted data will include the medication name, the
457 anatomical therapeutic chemical code, strength, prescribed quantity, collected quantity, prescription
458 date, collection date, prescriber's profession, and workplace. The assessment of the number of
459 instances of non-adherence will be conducted by the researchers.

460 *Healthcare Utilisation*

461 Unplanned hospital revisits, readmissions, emergency department visits, and time to these hospital
462 revisits within 90 days will be extracted from the EHR. The assessment whether the hospital
463 readmissions were potentially medication-related will be conducted retrospectively with the AT-
464 HARM10 tool [49] through information from the EHR. The assessment will be conducted by one
465 clinical pharmacist and one physician who are not otherwise involved in the study. Initially, they will

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

independently evaluate each case, followed by a discussion to reach consensus on cases where their initial assessment (e.g., whether a readmission is potentially medication-related) differed.

Process evaluation

A mixed-method approach, combining both quantitative and qualitative methods, will be used for a process evaluation to assess adherence to the study protocol and explore the implementation of the intervention. The evaluation will be guided by the framework for process evaluation developed by the UK Medical Research Council [52].

Quantitative Process Evaluation

The quantitative process evaluation will include all patients in the study to gain insight into the extent of intervention implementation, the degree to which some intervention components may already be in place during the control period, and adherence to the study protocol. The following data will be collected from the EHR:

- The proportion of control and intervention patients who received a discharge letter.
- The proportion of control and intervention patients for whom the clinical pharmacist prepared a medication discharge documentation.
- The proportion of intervention patients who received the information package.
- The proportion of control and intervention patients for whom the physician used the medication discharge documentation prepared by the pharmacist. This is measured by manually comparing the content of the prepared medication discharge documentation by the pharmacist with the actual medication summary in the discharge letter and final note written by the physician.
- The proportion of intervention patients who are reminded by the pharmacist to review the information package.
- The proportion of intervention patients who wish to have an informal caregiver present at the discharge consultation, and the proportion of those cases where the pharmacists contacts the informal caregiver to be present.

- The proportion of intervention patients who wish to have a follow-up call with a pharmacist after discharge, received the follow-up call, and whether it led to any pharmacist intervention, including details of the intervention.

Additional data collection methods:

- The proportion of all employed physicians and clinical pharmacists at the study wards who attend the training sessions. All HCPs attending the training sessions will be registered by the researchers. Data on HCPs who complete digital training sessions will be extracted from the digital training platform.
- The response rate of PIMCH-Q, along with the distribution method (paper, telephone, or digital). This will be extracted from REDCap.
- The proportion of control and intervention patients who recall having a discharge consultation, whether they wished to have an informal caregiver present, whether an informal caregiver was actually present, their desire for a follow-up call, and whether they received one. For control patients, these questions aim to determine the extent to which intervention components are performed as part of standard care. Additionally, for intervention patients, the proportion of patients who recall receiving the information package (intervention component 1) and their perception of it will be asked. These questions will be sent to patients alongside the PIMCH-Q.
- The duration of each follow-up call conducted by the pharmacist (intervention component 4). This will be recorded by the pharmacists.

Qualitative Process Evaluation

To gain a deeper understanding of how the intervention was implemented, a qualitative process evaluation involving HCP and patient interviews is planned to be conducted immediately after the last patient is discharged in the study. The detailed planning for this evaluation has not yet been finalised.

Sample size calculation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The sample size calculation is based on the primary outcome, which is the quality of medication-related discharge documentation measured using the CMDD-M. The intervention will be deemed successful if the average score is significantly higher in the intervention group compared to the control group. For the calculation, we assumed an evenly distributed sample between the two groups and set the target difference in CMDD-M scores at one point. This conservative target was chosen as it represents the smallest measurable step in the instrument. In practice, a one-point difference may indicate the inclusion of medication changes in the discharge letter or discharge summary. Such an improvement reflects a critical enhancement in quality, with important implications for patient safety and continuity of care. Data from the pilot studies indicated that the baseline value for CMDD-M was 3.9 (SD 2.6) (Nordin J, Berlin K, Sabouni Y, du Thinh C, *et al.*: Facilitating patient empowerment at hospital discharge: A pilot study testing the feasibility of the IMPACT-care intervention, unpublished). Due to the maximum score limit in CMDD-M, the variance in scores is expected to differ between the control and intervention periods. This difference arises as scores may cluster near the upper limit, particularly in the intervention period where improved performance is anticipated, potentially leading to reduced variability compared to the control period. A two-sided t-test with Welch's correction for degrees of freedom (to account for the variance difference between groups) was used. A power of 0.8 was considered sufficient to detect an increase, with a 5% two-sided significance level. Based on these assumptions, a sample size of 115 patients per group, for a total of 230 patients, is required.

Additionally, a permutation test using the Mann-Whitney U-test was performed to assess the robustness of the t-test, yielding similar results.

Statistical analysis

A full statistical analysis plan (SAP) will be finalised prior to any analyses. Statisticians from the Uppsala Clinical Research Center (UCR) will oversee the statistical analyses. The primary analysis will follow the ITT principle, including all included patients in their assigned groups, regardless of

protocol adherence. Additional analyses will include per-protocol (PP) analyses, i.e. excluding patients with protocol violations.

Descriptive analyses of the study population will be performed, with continuous data presented as mean $\pm$ standard deviation (SD) for normally distributed variables or as median and range for non-normally distributed variables. Categorical variables will be reported as frequencies and percentages. All outcomes will be summarised by study group, overall and by ward, descriptively. Comparative statistics between study groups will be conducted, with all statistical tests being two-sided and a p-value less than 0.05 considered statistically significant.

Models for analysing primary and secondary outcomes will include both unadjusted and fully adjusted analyses. Adjustments will account for age, gender, education level, ward type (geriatric or surgical), number of medication changes persisting post-discharge, number of medications at discharge, support by automatic dose-dispensation of medications, and duration of hospitalisation. Effect estimates, including odds ratios, hazard ratios, and rate ratios will be presented with 95 % CI and p-values.

Primary outcome analysis

Linear regression models with robust standard errors will be used to estimate the effect of the treatment groups on the CMDD-M score. The results will be reported as effect estimates. A sensitivity analysis of the primary outcome will be performed using a permutation-based Wilcoxon non-parametric test.

Secondary outcome analysis

Logistic regression will be used to analyse the prevalence of patients achieving the maximum score (9 points) on the CMDD-M, with results presented as odds ratios. The PIMCH-Q score will be analysed using linear regression models, evaluating the three dimensions both separately and in total. Differences in the number of instances of non-adherence to medication changes persisting post-discharge will be assessed using quasi-Poisson regression models, with results reported as rate

1
2
3 568 rations. Logistic regression models will be used to analyse the prevalence of patients who are fully
4
5 569 adherent to medication changes persisting post-discharge, with results reported as odds ratio.
6
7 570 The difference in the prevalence of patients with unplanned hospital revisits, unplanned
8
9
10 571 readmissions, emergency department visits and medication-related readmissions at 7, 30, and 90
11
12 572 days post-discharge will be compared with logistic regression models, with results presented as odds
13
14 573 ratios. Time to first unplanned hospital revisit, time to first unplanned readmission, and time to first
15
16 574 emergency department visit will be analysed using Cox proportional hazards models. Patients who
17
18 575 do not experience the event by the end of the study period or are lost to follow-up will be censored
19
20 576 at their last known follow-up time, while patients who die before experiencing the event will be
21
22 577 censored at the time of death. Results will be reported as hazard ratios.
23
24 578 *Exploratory analyses*
25
26 579 To analyse data collected at multiple regular intervals before and after the intervention, an ITS-
27
28 580 analysis will be performed. A linear regression model will be estimated as follows:
29
30
31
32
33 581 $Y=b_0+b_1T+b_2I+e$
34
35 582 Where:
36
37 583 Y: Outcome variable (CMDD-M score, prevalence of patients achieving the maximum score on
38
39 584 CMDD-M, PIMCH-Q score, or the number of non-adherence instances to medication changes
40
41 585 persisting post-discharge)
42
43 586 b_0 : Intercept, representing the expected value of the outcome variable (Y) at baseline (T = 0 and I =
44
45 587 0).
46
47
48 588 b_1 : Time effect, indicating the change of the outcome variable (Y) for each day passed, regardless of
49
50 589 the intervention.
51
52
53 590 T: Time in days passed from the start of the study, capturing natural changes in the outcome over
54
55 591 time.
56
57 592 b_2 : Intervention effect, representing the difference in the outcome variable (Y) between pre-
58
59 593 intervention (I = 0) and post-intervention (I = 1) periods, after accounting for time trends.
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

I: Dummy variable indicating whether the observation was collected before (0) or after (1) intervention, enabling comparison outcomes before and after the intervention.
e: Error term, capturing random noise or unexplained variation in the outcome variable (Y).

This model will allow us to investigate whether there is an immediate effect following the intervention. Results will be presented as regression estimates with 95% CI and p-values. This analysis will be conducted for the following outcomes: CMDD-M score, prevalence of patients achieving the maximum score on CMDD-M, PIMCH-Q score (the three dimensions separately and total score), the number of non-adherence instances to medication changes persisting post-discharge, and prevalence of patients who are fully adherent to medication changes.

Process evaluation

Quantitative data from the process evaluation will be presented with descriptive statistics by study group and in total. No formal statistical tests will be performed.

Public and patient involvement

Our research team includes two public representatives: CB, who holds political duties advocating for patients, and UE, who serves as the chairperson of an association representing relatives of older patients. Both have actively contributed to the design and development of this intervention study. Additionally, we engaged a broader panel of five public representatives, all of whom are either members of senior associations or have experience with hospitalised care. This panel reviewed and provided suggestions to improve the wording of the consent form for study inclusion and the PIMCH-Q sent to patients. They also played a key role in developing the information package for intervention component 1, offering feedback on its design and content.

ETHICS AND DISSEMINATION

This study involves human subjects and the handling of sensitive personal health data. Although, there is a risk associated with collecting sensitive patient data, we will minimise these risks by adhering to the General Data Protection Regulation (GDPR) [53], and the Declaration of Helsinki [54].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

All participants will provide written informed consent before participation. The study has been approved by the Ethical Review Authority in Sweden (registration no. 2023-03518-01 and 2024-04079-02).

The aim of this intervention study is to evaluate whether a novel approach to medication-related discharge communication can improve patient care. The comparator chosen for this study is the current standard discharge process (care as usual), selected because it reflects the routine practices patients experience in the study settings and provides a relevant baseline for evaluating the intervention's impact. During the intervention period, in addition to the usual care, the intervention focuses on enhancing the quality of medication-related communication at discharge, involving patients and/or caregivers in discussions with HCPs, and offering a follow-up call after discharge to reinforce information retention. During the clinical pharmacists' follow-up phone calls with patients in the intervention group, new issues may be identified that need attention. If the pharmacist making the call is not the appropriate person to handle these issues, they will consult with another suitable HCP to ensure the problem is addressed.

We plan to publish the results of the main trial and any sub-studies in international peer-reviewed open-access journals, as well as present them at national and international conferences. The trial is expected to result in multiple published manuscripts, contribute to at least one PhD thesis, and support improved implementation of current Swedish regulations for medication-related discharge communication [36].

REFERENCES

1. United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects 2022: Summary of Results [Internet]. United Nations; 2022. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp_2022_summary_of_results.pdf
2. Centers for Disease Control and Prevention. Persons with hospital stays in the past year, by selected characteristics: United States, selected years 1997–2018 [Internet]. [cited 2023 Feb 20]. Available from: <https://www.cdc.gov/nchs/data/hus/2019/040-508.pdf>

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

- 647 3. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk
648 factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*
649 [Internet]. 2014 Dec 1;9:2079–86. Available from: <http://dx.doi.org/10.2147/CIA.S71178>
- 650 4. Hoel RW, Giddings Connolly RM, Takahashi PY. Polypharmacy Management in Older Patients.
651 *Mayo Clin Proc* [Internet]. 2021 Jan;96(1):242–56. Available from:
652 <http://dx.doi.org/10.1016/j.mayocp.2020.06.012>
- 653 5. Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of
654 the Recent Literatures. *Bull Emerg Trauma* [Internet]. 2019 Oct;7(4):339–46. Available from:
655 <http://dx.doi.org/10.29252/beat-070401>
- 656 6. Kempen TGH, Hedman AN, Hadziosmanovic N, Lindner KJ, Melhus H, Nielsen EI, Sulku J,
657 Gillespie U. Risk factors for and preventability of drug-related hospital revisits in older patients:
658 A post-hoc analysis of a randomized clinical trial. *Br J Clin Pharmacol* [Internet]. 2023
659 May;89(5):1575–87. Available from: <http://dx.doi.org/10.1111/bcp.15621>
- 660 7. El Morabet N, Uitvlugt EB, van den Bemt BJB, van den Bemt PMLA, Janssen MJA, Karapinar-
661 Çarkit F. Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic
662 Review. *J Am Geriatr Soc* [Internet]. 03 2018;66(3):602–8. Available from:
663 <http://dx.doi.org/10.1111/jgs.15244>
- 664 8. World Health Organization. Transitions of Care: Technical Series on Safer Primary Care
665 [Internet]. World Health Organization; 2016 [cited 2024 Mar 24]. Available from:
666 <https://www.who.int/publications/i/item/9789241511599>
- 667 9. Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, Harchowal J, Raftery J,
668 Rajkumar C, on behalf of the PRIME study group. Incidence and cost of medication harm in
669 older adults following hospital discharge: a multicentre prospective study in the UK: Incidence
670 and cost of medication harm in older adults. *Br J Clin Pharmacol* [Internet]. 2018
671 Aug;84(8):1789–97. Available from: <http://dx.doi.org/10.1111/bcp.13613>
- 672 10. Spencer RA, Spencer SEF, Rodgers S, Campbell SM, Avery AJ. Processing of discharge summaries
673 in general practice: a retrospective record review. *Br J Gen Pract* [Internet]. 2018
674 Aug;68(673):e576–85. Available from: <http://dx.doi.org/10.3399/bjgp18X697877>
- 675 11. Caleres G, Modig S, Midlöv P, Chalmers J, Bondesson Å. Medication Discrepancies in Discharge
676 Summaries and Associated Risk Factors for Elderly Patients with Many Drugs. *Drugs Real World*
677 *Outcomes* [Internet]. 2020 Mar;7(1):53–62. Available from: [http://dx.doi.org/10.1007/s40801-](http://dx.doi.org/10.1007/s40801-019-00176-5)
678 019-00176-5
- 679 12. Cam H, Wennlöf B, Gillespie U, Franzon K, Nielsen EI, Ling M, Lindner KJ, Kempen TGH,
680 Källemark Sporrang S. The complexities of communication at hospital discharge of older
681 patients: a qualitative study of healthcare professionals' views. *BMC Health Serv Res* [Internet].
682 2023 Nov 6;23(1):1211. Available from: <http://dx.doi.org/10.1186/s12913-023-10192-5>
- 683 13. Knight DA, Thompson D, Mathie E, Dickinson A. “Seamless care? Just a list would have helped!”
684 Older people and their carer's experiences of support with medication on discharge home from
685 hospital. *Health Expect* [Internet]. 2013 Sep;16(3):277–91. Available from:
686 <http://dx.doi.org/10.1111/j.1369-7625.2011.00714.x>
- 687 14. Blozik E, Signorell A, Reich O. How does hospitalization affect continuity of drug therapy: an
688 exploratory study. *Ther Clin Risk Manag* [Internet]. 2016 Aug;12:1277–83. Available from:

1
2
3 689 <http://dx.doi.org/10.2147/tcrm.s109214>
4
5 690 15. Graabæk T, Terkildsen BG, Lauritsen KE, Almarsdóttir AB. Frequency of undocumented
6 691 medication discrepancies in discharge letters after hospitalization of older patients: a clinical
7 692 record review study. *Ther Adv Drug Saf* [Internet]. 2019 Jun 16;10:2042098619858049.
8 693 Available from: <http://dx.doi.org/10.1177/2042098619858049>
9
10 694 16. Weetman K, Dale J, Spencer R, Scott E, Schnurr S. GP perspectives on hospital discharge letters:
11 695 an interview and focus group study. *BJGP Open* [Internet]. 2020 Jun 23;4(2). Available from:
12 696 <http://dx.doi.org/10.3399/bjgpopen20X101031>
13
14 697 17. Schwarz CM, Hoffmann M, Schwarz P, Kamolz LP, Brunner G, Sendlhofer G. A systematic
15 698 literature review and narrative synthesis on the risks of medical discharge letters for patients'
16 699 safety. *BMC Health Serv Res* [Internet]. 2019 Mar 12;19(1):158. Available from:
17 700 <http://dx.doi.org/10.1186/s12913-019-3989-1>
18
19 701 18. Caleres G, Bondesson Å, Midlöv P, Modig S. Elderly at risk in care transitions When discharge
20 702 summaries are poorly transferred and used -a descriptive study. *BMC Health Serv Res*
21 703 [Internet]. 2018 Oct 11;18(1):770. Available from: [http://dx.doi.org/10.1186/s12913-018-3581-](http://dx.doi.org/10.1186/s12913-018-3581-0)
22 704 0
23
24 705 19. Cam H, Kempen TGH, Eriksson H, Abdulreda K, Franzon K, Gillespie U. Assessment of requests
25 706 for medication-related follow-up after hospital discharge, and the relation to unplanned
26 707 hospital revisits, in older patients: a multicentre retrospective chart review. *BMC Geriatr*
27 708 [Internet]. 2021 Nov 2;21(1):618. Available from: [http://dx.doi.org/10.1186/s12877-021-02564-](http://dx.doi.org/10.1186/s12877-021-02564-5)
28 709 5
29
30 710 20. Rognan SE, Sporrang SK, Bengtsson K, Lie HB, Andersson Y, Mowé M, Mathiesen L. Discharge
31 711 processes and medicines communication from the patient perspective: A qualitative study at an
32 712 internal medicines ward in Norway [Internet]. *Health Expectations*. 2021. Available from:
33 713 <http://dx.doi.org/10.1111/hex.13232>
34
35 714 21. Flink M, Ekstedt M. Planning for the Discharge, not for Patient Self-Management at Home - An
36 715 Observational and Interview Study of Hospital Discharge. *Int J Integr Care* [Internet]. 2017 Nov
37 716 13;17(6):1. Available from: <http://dx.doi.org/10.5334/ijic.3003>
38
39 717 22. Cam H, Franzon K, Sporrang SK, Kempen TGH, Bernsten C, Nielsen EI, Gustavsson L, Moosavi E,
40 718 Lindmark S, Ehlin U, Sjölander M, Lindner KJ, Gillespie U. "you're just thinking about going
41 719 home": Exploring person-centred medication communication with older patients at hospital
42 720 discharge. *Health Expect* [Internet]. 2024 Oct 1 [cited 2024 Oct 16];27(5):e70065. Available
43 721 from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/hex.70065>
44
45 722 23. Ozavci G, Bucknall T, Woodward-Kron R, Hughes C, Jorm C, Joseph K, Manias E. Knowledge and
46 723 Power Relations in Older Patients' Communication About Medications Across Transitions of
47 724 Care. *Qual Health Res* [Internet]. 2021 Dec;31(14):2678–91. Available from:
48 725 <http://dx.doi.org/10.1177/10497323211043494>
49
50 726 24. Ozavci G, Bucknall T, Woodward-Kron R, Hughes C, Jorm C, Joseph K, Manias E. A systematic
51 727 review of older patients' experiences and perceptions of communication about managing
52 728 medication across transitions of care. *Res Social Adm Pharm* [Internet]. 2021 Feb;17(2):273–91.
53 729 Available from: <http://dx.doi.org/10.1016/j.sapharm.2020.03.023>
54
55 730 25. Kaplan RM, Frosch DL. Decision making in medicine and health care. *Annu Rev Clin Psychol*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 731 [Internet]. 2005;1:525–56. Available from:
732 <http://dx.doi.org/10.1146/annurev.clinpsy.1.102803.144118>
- 733 26. Maly RC, Bourque LB, Engelhardt RF. A randomized controlled trial of facilitating information
734 giving to patients with chronic medical conditions: effects on outcomes of care. *J Fam Pract*
735 [Internet]. 1999 May;48(5):356–63. Available from:
736 <https://www.ncbi.nlm.nih.gov/pubmed/10334612>
- 737 27. Pel-Littel RE, Snaterse M, Teppich NM, Buurman BM, van Etten-Jamaludin FS, van Weert JCM,
738 Minkman MM, Scholte Op Reimer WJM. Barriers and facilitators for shared decision making in
739 older patients with multiple chronic conditions: a systematic review. *BMC Geriatr* [Internet].
740 2021 Feb 6;21(1):112. Available from: <http://dx.doi.org/10.1186/s12877-021-02050-y>
- 741 28. Bagge M, Norris P, Heydon S, Tordoff J. Older people's experiences of medicine changes on
742 leaving hospital. *Res Social Adm Pharm* [Internet]. 2014 Sep;10(5):791–800. Available from:
743 <http://dx.doi.org/10.1016/j.sapharm.2013.10.005>
- 744 29. Eibergen L, Janssen MJA, Blom L, Karapinar-Çarkit F. Informational needs and recall of in-
745 hospital medication changes of recently discharged patients. *Res Social Adm Pharm* [Internet].
746 2018 Feb;14(2):146–52. Available from: <http://dx.doi.org/10.1016/j.sapharm.2017.01.006>
- 747 30. The IMPACT-care project [Internet]. Akademiska sjukhuset [Uppsala University Hospital]. [cited
748 2024 Mar 26]. Available from: <https://www.akademiska.se/forskning-och-utbildning/forskningsrelaterat/har-bedriver-vi-forskning/impact-care/the-impact-care-project/>
- 750 31. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann
751 H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC,
752 Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for
753 clinical trials. *Ann Intern Med* [Internet]. 2013 Feb 5 [cited 2024 Jun 24];158(3):200–7. Available
754 from: <https://www.acpjournals.org/doi/10.7326/0003-4819-158-3-201302050-00583>
- 755 32. Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow
756 A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia
757 M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ,
758 Offringa M. Guidelines for reporting outcomes in trial protocols: The SPIRIT-outcomes 2022
759 extension: The SPIRIT-outcomes 2022 extension. *JAMA* [Internet]. 2022 Dec 20 [cited 2024 Dec
760 2];328(23):2345–56. Available from:
761 https://jamanetwork.com/journals/jama/articlepdf/2799547/jama_butcher_2022_sc_220006_1670872541.22449.pdf
- 763 33. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V,
764 Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie
765 S. Better reporting of interventions: template for intervention description and replication
766 (TIDieR) checklist and guide. *BMJ* [Internet]. 2014 Mar 7 [cited 2024 Dec 2];348:g1687. Available
767 from: <https://www.bmj.com/content/348/bmj.g1687.abstract>
- 768 34. Cam H, Franzon K, Kempen TGH, Nielsen I E, Gustavsson L, Moosavi E, Sjölander M, Sporrang
769 Källemark S, Lindner KJ, Gillespie U. Involvement of older hospitalised patients in medication
770 decisions: A naturalistic observation and interview study. Manuscript in preparation.
- 771 35. Region Uppsala och samtliga kommuner i Uppsala län [Region Uppsala and the municipalities of
772 Uppsala]. Samverkan vid utskrivning från slutenvård [Collaboration at hospital discharge]
773 [Internet]. 2022 [cited 2024 Mar 23]. Available from: <https://publikdocplus.regionuppsala.se/>

1
2
3 774 36. Socialstyrelsen [National Board of Health and Welfare]. Socialstyrelsens föreskrifter och
4 775 allmänna råd om ordination och hantering av läkemedel i hälso och sjukvården [The National
5 776 Board of Health and Welfare’s regulations and general guidelines on prescribing and handling of
6 777 medications in health care] [Internet]. 2017 [cited 2024 Mar 24]. Available from:
7 778 [https://www.socialstyrelsen.se/regler-och-riktlinjer/foreskrifter-och-allmanna-](https://www.socialstyrelsen.se/regler-och-riktlinjer/foreskrifter-och-allmanna-rad/konsoliderade-foreskrifter/201737-om-ordination-och-hantering-av-lakemedel-i-halso--och-sjukvarden/)
8 779 [rad/konsoliderade-foreskrifter/201737-om-ordination-och-hantering-av-lakemedel-i-halso--](https://www.socialstyrelsen.se/regler-och-riktlinjer/foreskrifter-och-allmanna-rad/konsoliderade-foreskrifter/201737-om-ordination-och-hantering-av-lakemedel-i-halso--och-sjukvarden/)
9 780 [och-sjukvarden/](https://www.socialstyrelsen.se/regler-och-riktlinjer/foreskrifter-och-allmanna-rad/konsoliderade-foreskrifter/201737-om-ordination-och-hantering-av-lakemedel-i-halso--och-sjukvarden/)
11
12 781 37. Lawton R, Murray J, Baxter R, Richardson G, Cockayne S, Baird K, Mandefield L, Brealey S,
13 782 O’Hara J, Foy R, Sheard L, Cracknell A, Breckin E, Hewitt C, PACT research team. Evaluating an
14 783 intervention to improve the safety and experience of transitions from hospital to home for
15 784 older people (Your Care Needs You): a protocol for a cluster randomised controlled trial and
16 785 process evaluation. *Trials* [Internet]. 2023 Oct 14;24(1):671. Available from:
17 786 <http://dx.doi.org/10.1186/s13063-023-07716-z>
19
20 787 38. Sansoni JE, Grootemaat P, Duncan C. Question Prompt Lists in health consultations: A review.
21 788 *Patient Educ Couns* [Internet]. 2015 Jun 3; Available from:
22 789 <http://dx.doi.org/10.1016/j.pec.2015.05.015>
23
24 790 39. Svensberg K, Kaae S, Mottelson NB, Persson CL. Identifying critical elements in using Question
25 791 Prompt Lists at the pharmacy counter to induce patient activation—using principles of
26 792 conversation analysis. *Res Social Adm Pharm* [Internet]. 2024 Nov 4 [cited 2024 Nov 19];
27 793 Available from: <http://dx.doi.org/10.1016/j.sapharm.2024.10.008>
28
29 794 40. Ljungberg Persson C, Al-Nuaimi A, Esmaeili N, Svensberg K. Patients’ attitudes towards using a
30 795 question prompt list in community pharmacies. *Patient Educ Couns* [Internet]. 2023 Oct
31 796 1;115(107862):107862. Available from:
32 797 <https://www.sciencedirect.com/science/article/pii/S0738399123002422>
34
35 798 41. Tong EY, Roman CP, Mitra B, Yip GS, Gibbs H, Newnham HH, Smit DV, Galbraith K, Dooley MJ.
36 799 Reducing medication errors in hospital discharge summaries: a randomised controlled trial.
37 800 *Med J Aust* [Internet]. 2017 Jan 16;206(1):36–9. Available from:
38 801 <http://dx.doi.org/10.5694/mja16.00628>
39
40 802 42. Elliott RA, Tan Y, Chan V, Richardson B, Tanner F, Dorevitch MI. Pharmacist-Physician
41 803 Collaboration to Improve the Accuracy of Medication Information in Electronic Medical
42 804 Discharge Summaries: Effectiveness and Sustainability. *Pharmacy (Basel)* [Internet]. 2019 Dec
43 805 30;8(1). Available from: <http://dx.doi.org/10.3390/pharmacy8010002>
45
46 806 43. Uitvlugt EB, Siegert CEH, Janssen MJA, Nijpels G, Karapinar-Çarkit F. Completeness of
47 807 medication-related information in discharge letters and post-discharge general practitioner
48 808 overviews. *Int J Clin Pharm* [Internet]. 2015 Dec;37(6):1206–12. Available from:
49 809 <http://dx.doi.org/10.1007/s11096-015-0187-z>
50
51 810 44. Hesselink G, Flink M, Olsson M, Barach P, Dudzik-Urbaniak E, Orrego C, Toccafondi G, Kalkman
52 811 C, Johnson JK, Schoonhoven L, Vernooij-Dassen M, Wollersheim H, European HANDOVER
53 812 Research Collaborative. Are patients discharged with care? A qualitative study of perceptions
54 813 and experiences of patients, family members and care providers. *BMJ Qual Saf* [Internet]. 2012
55 814 Dec;21 Suppl 1:i39–49. Available from: <http://dx.doi.org/10.1136/bmjqs-2012-001165>
56
57 815 45. Tomlinson J, Cheong VL, Fylan B, Silcock J, Smith H, Karban K, Blenkinsopp A. Successful care
58 816 transitions for older people: a systematic review and meta-analysis of the effects of
59 817 interventions that support medication continu... - PubMed - NCBI. *Age Ageing* [Internet]. 2020

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 818 Feb 11 [cited 2020 Mar 16]; Available from: <https://www.ncbi.nlm.nih.gov/pubmed/32043116>
- 819 46. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: Truth and
820 consequences. *Am J Med Sci* [Internet]. 2016 Apr [cited 2024 Dec 4];351(4):387–99. Available
821 from: <https://pubmed.ncbi.nlm.nih.gov/27079345/>
- 822 47. Midlöv P, Deierborg E, Holmdahl L, Höglund P, Eriksson T. Clinical outcomes from the use of
823 Medication Report when elderly patients are discharged from hospital. *Pharm World Sci*
824 [Internet]. 2008 Dec;30(6):840–5. Available from: [http://dx.doi.org/10.1007/s11096-008-9236-](http://dx.doi.org/10.1007/s11096-008-9236-1)
825 1
- 826 48. Gilmore-Bykovskiy AL, Kennelty KA, DuGoff E, Kind AJH. Hospital discharge documentation of a
827 designated clinician for follow-up care and 30-day outcomes in hip fracture and stroke patients
828 discharged to sub-acute care. *BMC Health Serv Res* [Internet]. 2018 Feb 9 [cited 2024 Dec
829 4];18(1):103. Available from: <https://pubmed.ncbi.nlm.nih.gov/29426318/>
- 830 49. Kempen TGH, Hedström M, Olsson H, Johansson A, Ottosson S, Al-Sammak Y, Gillespie U.
831 Assessment tool for hospital admissions related to medications: development and validation in
832 older patients. *Int J Clin Pharm* [Internet]. 2019 Feb;41(1):198–206. Available from:
833 <http://dx.doi.org/10.1007/s11096-018-0768-8>
- 834 50. Kempen TGH, Hedman A, Gillespie U. Drug-related emergency department visits in older
835 patients: an applicability and reliability study of an existing assessment tool. *Int J Clin Pharm*
836 [Internet]. 2022 Aug;44(4):1078–82. Available from: [http://dx.doi.org/10.1007/s11096-022-](http://dx.doi.org/10.1007/s11096-022-01456-x)
837 01456-x
- 838 51. REDCap - Research Electronic Data Capture [Internet]. REDCap. [cited 2024 Feb 20]. Available
839 from: <https://www.project-redcap.org/>
- 840 52. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP,
841 McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for
842 developing and evaluating complex interventions: update of Medical Research Council
843 guidance. *BMJ* [Internet]. 2021 Sep 30;374:n2061. Available from:
844 <http://dx.doi.org/10.1136/bmj.n2061>
- 845 53. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on
846 the protection of natural persons with regard to the processing of personal data and on the free
847 movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)
848 [Internet]. EUR-lex. [cited 2024 Sep 30]. Available from: [https://eur-lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32016R0679)
849 content/EN/TXT/?uri=celex%3A32016R0679
- 850 54. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles
851 for medical research involving human subjects. *JAMA* [Internet]. 2013 Nov 27;310(20):2191–4.
852 Available from: <http://dx.doi.org/10.1001/jama.2013.281053>
- 853 55. CASRAI. CRediT - Contributor Roles Taxonomy [Internet]. 2019 [cited 2024 Mar 30]. Available
854 from: <https://credit.niso.org/>
- 855

DECLARATIONS

Acknowledgements

We thank the other members of the IMPACT-care research group and public representative group, who are not listed as co-authors, for their contributions to the planning of this study protocol (in alphabetical order): Emma Bertilsson, Agneta Darberg, Ellinor Eriksson, Nils Lannergård Probst, Mia Ling, Karin Näslund-Westman, Gerd Waleij, and Björn Wennlöf. We also thank the patients who participated in the pilot studies, as well as Karin Svensberg, the clinical pharmacists, public representative panel, designers, and film crew who were involved in developing the information package. We are grateful to Rebecca Lawton and Jenni Murray for inspiring us to develop the information package and data collection forms. Additionally, we acknowledge the students who contributed to various aspects of preparations for this study protocol (in alphabetical order): Ludwig Bernhardt, Kristoffer Berlin, Mari Bsada, Harleen Cheema, Melina Khashi, Maryam Mohamed, Jessica Nordin, Carolina Ravn, Yamen Sabouni, and Cecilie du Thinh.

Authors' contributions

Contributions by each author according to the Contributor Roles Taxonomy (CRediT)[55]: conceptualisation: all authors; funding acquisition: KF, TK, EN, KJL, CB, and UG; project administration: HC, KF, VÖ, and UG; methodology: all authors; writing - original draft: HC; writing - review & editing: all authors. All authors have read and agreed to the published version of the manuscript.

Funding statement

This work was supported by The Kamprad Foundation for Entrepreneurship, Research & Charity [Familjen Kamprads stiftelse] grant number 20190109 and Regional Research Council Mid Sweden [Sjukvårdsregionala forskningsrådet Mellansverige] grant number 967624. TK received postdoctoral research funding from the Elisabeth and Alfred Ahlqvist foundation (Sweden). Open access funding

880 was provided by Uppsala University. The funding bodies had no role in the design of the study, the
881 collection, analysis, interpretation of the data or the writing of the manuscript.

882 **Competing interests statement**

883 The authors declare no competing interests.

For peer review only

Dina läkemedel: från sjukhuset till hemmet

Ett stöd under sjukhusvistelsen för att
förbereda dig inför att komma hem



Hur denna broschyr kan användas

När man är inlagd på sjukhus händer det många saker och det kan vara så att man inte förstår eller känner sig bekväm med allt som sker.

Denna informationsbroshyr är tänkt som ett stöd för dig och dina eventuella närstående för att få mer kunskap om din vård under tiden på sjukhuset och när du kommer hem.

Den är indelad i fyra avsnitt och innehåller information och förslag på punkter att diskutera med vårdpersonalen eller dina eventuella närstående.

Du kan markera de punkter du skulle vilja diskutera med vårdpersonalen. Du kan också anteckna egna frågor som du vill ta upp.

1 Min sjukhusvistelse


2 Mina läkemedel

3 Inför att komma hem (utskrivning)

4 Råd när jag är hemma

Scanna med en
mobilkamera för
informationsfilm





Min sjukhusvistelse

För att du ska kunna sköta om din egen vård och läkemedelsbehandling när du kommer hem underlättar det om du har kunskap om det som har hänt på sjukhuset.

Det kan du få genom att:

- Prata med vårdpersonalen om det som händer och om det är något du undrar över.
- Be om att få vara med i diskussionerna kring din vård och läkemedelsbehandling.

Punkter jag skulle vilja diskutera

Markera vad du skulle vilja diskutera och/eller skriv ner andra frågor.

- Vad har jag behandlats för på sjukhuset?
- Vad är planen för min vård på sjukhuset?
- Vad är planen för min vård efter att jag kommer hem?
- Vad för hjälp och stöd kan jag få när jag kommer hem?
- Hur kan mina eventuella närstående hjälpa mig?



Mina läkemedel

Det är vanligt att det görs ändringar i din läkemedelsbehandling när du är på sjukhus och det kan vara svårt att hålla sig uppdaterad.

Du kan fråga vårdpersonalen om dina läkemedel. Du kan också diskutera hur du ska ta dem hemma och om det är något du behöver öva på.

Punkter jag skulle vilja diskutera

Markera vad du skulle vilja diskutera och/eller skriv ner andra frågor.

- Vilka läkemedel tar jag och varför?
- Hur och när ska jag ta mina läkemedel och är det något särskilt jag ska tänka på?
- Vilka ändringar i min läkemedelsbehandling är gjorda på sjukhuset och varför?
- Vilken effekt kan jag förvänta mig av mina nya läkemedel?
- Vilka biverkningar ska jag vara uppmärksam på?
- Vart ska jag vända mig om jag har frågor eller om jag upplever att jag inte mår bra av mina läkemedel?
- Kan jag få öva på att ta mina läkemedel (t.ex. sprutor eller inhalatorer) medan jag är på sjukhuset?
- Vilket stöd finns om jag skulle behöva hjälp med mina läkemedel hemma?



Inför att komma hem (utskrivning)

Utskrivning innebär att det är dags för dig att lämna sjukhuset, och då kan det vara mycket information som du och dina eventuella närstående ska få och att diskutera. Informationen ska göra så att du vet vad du kan förvänta dig när du kommer hem och hur du kan få hjälp om du behöver det.

Det här är information du har **rätt att få** innan du lämnar sjukhuset:

- **Utskrivningssamtal:** ett samtal du kommer ha med en läkare för att gå igenom det som hänt under tiden på sjukhuset och planen framåt. Det kan vara bra om en eventuell närstående är med vid samtalet.
- **Utskrivningsmeddelande:** skriftlig information om det som har hänt under tiden på sjukhuset, vilka förändringar som har gjorts av dina läkemedel, samt vad planen är för nästa steg i din vård. Läs och spara utskrivningsmeddelandet och visa det för dina eventuella närstående.
- **Läkemedelslista:** en skriftlig lista med de läkemedel som du ska fortsätta ta när du kommer hem. Använd denna och släng dina tidigare listor.



Checklista inför din utskrivning

Stäm av checklistan med vårdpersonalen för att säkerställa att allt är i ordning innan du lämnar sjukhuset.

- ☐ Jag vet vilka symtom jag ska vara uppmärksam på.
- ☐ Jag vet vilka läkemedel jag ska ta när jag kommer hem och hur jag ska ta dem.
- ☐ Jag vet vart jag ska vända mig för att få nya recept på mina läkemedel.
- ☐ Jag vet vart jag kan vända mig om jag mår sämre eller har frågor om mina läkemedel.
- ☐ Jag vet hur hemtjänst och/eller hemsjukvård kommer att hjälpa mig med mina läkemedel (om aktuellt).
- ☐ Jag vet vilken uppföljande kontakt med vården som är planerad för mig.
- ☐ Jag har fått mitt utskrivningsmeddelande.
- ☐ Jag har fått min nya läkemedelslista.
- ☐ Jag har haft ett utskrivningssamtal med läkare.



Råd när du är hemma



Mina läkemedel

- Om du framöver har frågor om dina läkemedel kan du kontakta ett apotek eller den vårdcentral eller mottagning du tillhör.
- Om du inte kommer ihåg vilka ändringar som gjorts med dina läkemedel på sjukhuset kan du titta i utskrivningsmeddelandet och läkemedelslistan.
- Utskrivningsmeddelandet och läkemedelslistan du fick från sjukhuset finns även i din journal på 1177.se. Du kan också kontakta din vårdcentral för att få ut informationen igen.
- Använd alltid den senaste läkemedelslistan som du fått från sjukhuset eller din vårdcentral. Listan som du kan få från apoteket innehåller inte alltid de ändringar som har gjorts, så du ska inte följa den.
- De läkemedel du inte längre använder ska lämnas in på ett apotek.
- Kom ihåg att förnya dina recept i god tid.



Sök hjälp om du blir sämre

- Du kan känna kvarvarande symtom när du just kommit hem. Kontakta din vårdcentral eller ring sjukvårdsrådgivningen ([1177](http://1177.se)) om symtomen inte försvinner, blir värre eller om du får andra symtom.
- Ring [112](http://112.se) eller åk in till närmaste akutmottagning om du är rädd för att ha drabbats av något allvarligt eller livshotande.

Anteckningssida

For peer review only

Complete Medication Documentation at Discharge Measure (CMDD-M)
(Unofficial English version, translated from Swedish)

Item	Discharge letter (intended for the patient)	Points
1	The discharge letter includes a description of medication changes - 0 points: No - 1 point: Yes	0-1
2	All medication changes are explicitly* stated (including duration/end date if time-limited) - 0 points: No - 2 points: Yes	0 or 2
3	Reasons for all medication changes are stated - 2 points: The reason for all changes is included - 1 point: The reason for at least one change is included - 0 points: No reasons are stated - o Automatically scored 0 points if item 2 is scored 0	0-2
Discharge summary (intended for the next healthcare provider)		
4	Information about medication treatment is included in the discharge summary (sufficient if medications at discharge are listed, or if it is stated that medication changes have been made) - 0 points: No - 1 point: Yes	0-1
5	All medication changes are stated - 2 points: All medication changes are explicitly* stated - 1 point: All changes are stated in a general** way - 0 points: At least one change is missing, or incorrectly stated - o Automatically scored 0 points if item 4 is scored 0	0-2
Referral		
6	A referral is sent to the next healthcare provider - 0 points: No referral and medication changes were made - 1 point: Yes, or no referral needed (no medication changes made)	0-1
	Total	0-9

* Explicitly: For initiation and changes, state the medication name, strength, dose, dosage, and dosage form. For discontinuation state the medication name.

** General: For example, "Pain relief treatment initiated".

Standard Operating Procedure (SOP) for using the CMDD-M

General Guidelines for Assessment

Identifying medication changes

- Medications at admission: Check the historical medication list from the day of admission. (Note: Admission could have been in another department.)
- Medications at discharge: Check the historical medication list from the day of discharge.
- Not considered a change:
 - o Medications added or removed from the medication list during a medication reconciliation at admission (these are corrections, not changes) as noted in the doctor's or pharmacist's note.
 - o Over-the-counter creams that can be purchased without prescription, regardless of the change made.
- Examples of how to assess combination preparations:
 - o If Ramipril Comp is discontinued and Ramipril is initiated, this counts as 1 discontinuation and 1 initiation.
 - o If two separate medications are switched to a combination preparation this counts as 2 discontinuations and 1 initiation.

Item-Specific Guidelines for Assessment

Items 2 and 5

- For initiation or changes to a medication, then name, strength, dose, dosage, and dosage form must be explicitly stated.
- For discontinuation, only the name must be stated.
- Medications prescribed solely for use during the hospital stay do not need to be included, such as intravenous antibiotics, insulin, infusion fluids, and similar medications.

Item 3

- The reason for a medication change may be acceptable if stated in general terms such as "for the heart", depending on the recipient.

Item 5

- Examples of general ways to state medication changes include:
 - o "Blood pressure medication reduced"
 - o "Pain relief treatment initiated"
- Simply stating "new medications prescribed" is not sufficient.

Patient Involvement in Medication Communication at Hospital discharge Questionnaire
(PIMCH-Q)
(Unofficial English version, translated from Swedish)

Items	I strongly disagree	I disagree	I agree	I strongly agree	Don't know
While in hospital...					
1. I felt involved in decisions about my medication treatment that would continue after discharge (e.g., which changes would be made).					
2. I was offered the opportunity to have an informal caregiver present during the discharge consultation.					
3. I felt involved in decisions about the follow-up of my medication treatment.					
After returning home...					
4. I (and/or my informal caregiver) know what changes were made to my medication treatment in the hospital (e.g., new medications, medications I should no longer use, or changes in dosage).					
5. I (and/or my informal caregiver) know why my medication treatment was changed in the hospital (e.g., due to newly discovered atrial fibrillation or high blood pressure).					
6. I feel confident that I (and/or informal caregiver) can manage my medication treatment.					
7. I (and/or informal caregiver) know where to turn if I have questions about my medication treatment.					
8. I (and/or my relative) know how my medication treatment will be followed up.					

BMJ Open

Improved medication communication and patient involvement at care transitions (IMPACT-care): study protocol for a pre-post intervention trial in older hospitalised patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2025-099547.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Apr-2025
Complete List of Authors:	Cam, Henrik; Uppsala University, Department of Pharmacy Franzon, Kristin; Uppsala University, Department of Public Health and Caring Sciences Östman, Victoria; Uppsala University, Department of Pharmacy Kälvemark Sporrang, Sofia; Uppsala University, Department of Pharmacy Kempen, Thomas Gerardus Hendrik; Uppsala University, Department of Pharmacy Utrecht University, Utrecht Institute for Pharmaceutical Sciences Nielsen, Elisabet I; Uppsala University, Department of Pharmacy Lindner, Karl-Johan; Region Västmanland, Department of Pharmacy Ekelo, Beatrice; Region Västmanland, Department of Pharmacy Bernsten, Cecilia; Uppsala University, Department of Pharmacy Ehlin, Ulf; Östhammar Association of Relatives and Elderly People Lindmark, Stina; Uppsala University Hospital, Geriatrics Hadziosmanovic, Nermin; Uppsala Clinical Research Center Gillespie, Ulrika; Uppsala University, Department of Pharmacy
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Communication, Geriatric medicine, Patient-centred medicine
Keywords:	Clinical Protocols, Health Services for the Aged, Hospital to Home Transition, Medication Adherence, Patient-Centered Care, Pharmacists

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

TITLE

2

Improved medication communication and patient involvement at care

3

transitions (IMPACT-care): study protocol for a pre-post intervention trial in

4

older hospitalised patients

5

AUTHOR NAMES AND AFFILIATIONS

6

Henrik Cam (henrik.cam@uu.se)^a, Kristin Franzon (kristin.franzon@uu.se)^b, Victoria Östman

7

(victoria.ostman@uu.se)^a, Sofia Källemark Sporröng (sofia.kallemark-sporrong@uu.se)^a, Thomas

8

Gerardus Hendrik Kempen (thomas.kempen@uu.se)^{a,c}, Elisabet I Nielsen (elisabet.nielsen@uu.se)^a,

9

Karl-Johan Lindner (karl.johan.lindner@regionvastmanland.se)^d, Beatrice Ekelo

10

(beatrice.ekelo@regionvastmanland.se)^d, Cecilia Bernsten (cecilia.bernsten@klotblix.se)^a, Ulf Ehlin

11

(ulf.ehlin@telia.com)^e, Stina Lindmark (stina.lindmark@yahoo.se)^f, Nermin Hadziosmanovic^g

12

(Nermin.Hadziosmanovic@ucr.uu.se), Ulrika Gillespie (ulrika.gillespie@akademiska.se)^a

13

^a Department of Pharmacy, Uppsala University, Uppsala, Sweden

14

^b Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

15

^c Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

16

^d Department of Pharmacy, Region Västmanland, Västerås, Sweden

17

^e Östhammar Association of Relatives and Elderly People, Östhammar, Sweden

18

^f Geriatrics, Uppsala University Hospital, Uppsala, Sweden

19

^g Uppsala Clinical Research center, Uppsala, Sweden

20

Corresponding author:

21

Henrik Cam

22

Email: henrik.cam@uu.se

ABSTRACT

Introduction

Care transitions, particularly hospital discharge, present significant risks to patient safety. Deficient medication-related discharge communication is a major contributor, posing substantial risk of harm to older patients. This protocol outlines the Improved Medication Communication and Patient Involvement at Care Transitions (IMPACT-care) intervention study, designed to evaluate the effects of a multi-faceted intervention for older hospitalised patients on medication-related discharge communication compared to usual hospital care.

Methods and analysis

A pre-post intervention study will be conducted in two surgical and one geriatric ward of a university hospital in Sweden. The study will begin with a control period delivering usual care, followed by a training period and then an intervention period. The intervention comprises four components performed by clinical pharmacists: (1) an information package provided to patients and/or their informal caregivers, (2) preparation of medication-related discharge documentation, (3) facilitation of discharge communication, and (4) a follow-up call to patients or their informal caregiver. Eligible participants are aged ≥ 65 years, manage their own medications independently or with informal caregiver support, and are admitted to the study wards. Each study period (control and intervention) will last until 115 patients have been included. The primary outcome is the quality of medication-related discharge documentation, assessed using the Complete Medication Documentation at Discharge Measure (CMDD-M). Secondary outcomes include patients' perceptions of knowledge and involvement in discharge medication communication, and their sense of security in managing medication post-discharge; adherence to medication changes from hospitalisation that persist after discharge; and unplanned healthcare visits following discharge. A process evaluation is planned to explore how the intervention was implemented. Patient inclusion began in September 2024.

Ethics and dissemination

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489

1490

1491

[3,4]. One in six hospital admissions and one in five readmissions among older patients are medication-related [5,6], most of which are preventable [7]. Care transitions, particularly hospital discharges, pose significant risks to patient safety and is highlighted by the World Health Organization (WHO) as a focus for healthcare improvements [8]. More than one-third of older patients experience adverse drug reactions within eight weeks post-discharge [9], often attributed to poor communication and coordination between hospitals, subsequent healthcare providers, and patients or their informal caregivers [6,10–13]. Most hospitalised older patients experience changes to their medication regimens, which persist after discharge and should be effectively communicated to all individuals involved in their care [14,15].

Relying on written discharge notes and referrals to bridge communication gaps regarding medication changes and follow-up plans has proven unreliable, as this information is often delivered late or of insufficient quality [16–19]. Discharge consultations often lack structure and patient-centeredness, frequently being treated as a checklist item for healthcare professionals (HCPs) to complete before discharge [20–22]. Physicians tend to adopt an authoritative role in medication discussions, which can discourage older patients from actively participating in their medication management [23]. To foster patient involvement, HCPs should act as advocates rather than paternalistic figures [24]. Patient-centred communication at discharge is essential for equipping patients with the knowledge and confidence to manage their medications and self-care [20]. Involving patients in medical decisions is a key component of patient-centred care, leading to improved patient satisfaction and clinical outcomes, such as better glycaemic and blood pressure control [25,26]. However, older patients may be less inclined or unable to participate actively, often due to factors such as cognitive or physical impairments [27]. Many feel insufficiently empowered to engage in discussions about their medications and tend to rely on HCPs, following prescriptions without question [22,28]. Even when discharge information is presented in a structured format, older patients frequently struggle to retain details about their medications [29]. Informal caregivers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

97 can be vital in supporting patient involvement and bridging communication gaps between HCPs and
98 older patients [12,23].

99 To address these issues, the research project Improved Medication Communication and
100 Patient Involvement at Care Transitions (IMPACT-care) was initiated [30]. The project began with
101 exploratory studies of the discharge communication [12,19,22], ultimately leading to the
102 development of the intervention presented in this protocol.

103 **Aims and objectives**

104 The overall aim is to evaluate the effects of a multi-faceted intervention on improving medication-
105 related discharge communication for older hospitalised patients, compared to usual hospital care.

106 The primary objective is to assess the intervention’s impact on the quality of written
107 medication-related discharge documentation compared to usual hospital care. Secondary objectives
108 include evaluating the intervention's effect on patients' perceived involvement in discharge
109 medication communication and their confidence in post-discharge medication management, as well
110 as adherence to medication changes from hospitalisation that persist after discharge, and the need
111 for unplanned healthcare visits following discharge, all in comparison to usual hospital care.

112 **METHODS AND ANALYSIS**

113 This protocol was developed and reported in accordance with the Standard protocol items:
114 recommendations for interventional trials (SPIRIT) 2013 statement [31], the SPIRIT-outcomes 2022
115 extension [32], and the Template for intervention description and replication (TIDieR) checklist [33].

116 **Study design**

117 This prospective intervention study uses a pre-post design (Figure 1). Control patients will be
118 enrolled first (control period), followed by a training phase during which HCPs in the study wards will
119 be trained to implement the intervention. Once the HCPs have undergone training sessions, the
120 intervention period will start. Enrolment during both the control and intervention period will stop
121 once the target sample size is reached, with patient follow-up continuing for four months post-

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

discharge. Based on the pilot study, the control and intervention periods are each expected to last approximately six months, and the training phase will last around two months. Figure 1 provides a schematic overview of the study design. Study enrolment began in September 2024, and recruitment of participants for the intervention group is currently ongoing as of April 2025.

Rationale for study design

A randomised trial was deemed infeasible - neither at the patient level, due to contamination risks, nor at the ward level or as a stepped-wedge design, as these would require a large number of wards and exceed available resources. Consequently, a pre-post study design was selected, complemented by an interrupted time series (ITS) analysis for exploratory purposes. The ITS analysis, analysing data at regular intervals both before and after the intervention, allows for a more nuanced interpretation of the primary results by accounting for potential seasonal variations and changes in effect over time.

Settings

The study is conducted in two surgical wards and one geriatric ward at Uppsala University Hospital in Sweden. The surgical wards mainly handle emergency surgeries, as well as liver-pancreas, transplantation, oesophagus-stomach, endocrine, and colorectal surgeries. The geriatric ward treats older patients with complex acute medical and rehabilitation needs. These two clinical specialties were selected to assess whether the intervention could have an effect across various clinical settings.

Study population and recruitment

Patients aged 65 years or older, who manage their own medications either independently or with support from an informal caregiver, and are admitted to the study wards, are eligible for inclusion. An informal caregiver is defined as an unpaid individual, often a family member, who assists the patient with daily activities, healthcare communication, and medication management. Exclusion criteria apply if patients meet any of the pre-determined conditions that would hinder the successful

1
2
3 147 delivery of the intervention or the reliable collection of outcome data (a detailed list is provided in
4
5 148 Table 1).
6
7
8 149 The researchers, who are employed by the hospital, screen the admission lists of the study
9
10 150 wards daily on weekdays to identify eligible patients, who are then asked for inclusion by the
11
12 151 researchers or clinical pharmacists on the ward. Eligibility is primarily determined through the
13
14 152 patient's electronic health records (EHR), with any uncertainties resolved through discussions with
15
16 153 HCPs at the study wards. Once identified, patients are informed both verbally and in writing, and
17
18
19 154 written informed consent (Supplementary material I) is requested. Patients meeting exclusion
20
21 155 criteria 10-15 in Table 1 are excluded at discharge.
22

23 156 During the recruitment of control patients, all patients fulfilling the inclusion and exclusion
24
25 157 criteria are invited to participate. During the intervention period, patient inclusion is determined
26
27
28 158 based on the capacity of the pharmacists performing the intervention. The pharmacists' capacity will
29
30 159 be evaluated through regular feedback discussions, ensuring that the inclusion process aligns with
31
32 160 their workload. If the number of eligible patients exceeds the pharmacists' capacity, the pharmacist,
33
34 161 in collaboration with the research team, will determine how many eligible patients can be included.
35
36
37 162 To prioritise which patients to include, a random priority number will be generated for each eligible
38
39 163 patient at the study ward level using Microsoft Excel, with those assigned the highest priority
40
41 164 included first.
42
43

44 165 **Table 1.** The inclusion and exclusion criteria in the study. Patients meeting exclusion criteria 1-9 are
45 166 excluded at the time of hospital admission, while those meeting exclusion criteria 10-15 are
46 167 excluded at the time of discharge.
47

Inclusion criteria	
1.	65 years or older.
2.	Manages their own medications, either independently or with support from an informal caregiver, prior to inclusion.
Exclusion criteria	
Checked at hospital admission	
1.	Registered in a region outside the study hospital (limited data availability).
2.	Admitted from a nursing home (no own medication management prior to admission).

3. Unable to receive information or provide consent independently (due to cognitive impairment or unresponsiveness).
4. Already included in the study.
5. Patient delocalised to the study ward with another medical discipline responsible for the patient's care (formally, no study ward patient).
6. In a late palliative phase prior to inclusion (intervention not suitable).
7. Unable to communicate in Swedish (hindering intervention delivery).
8. Has restricted personal information in the EHR (limited data availability).
9. Admitted for transplantation (intervention not suitable).

Checked at hospital discharge

10. Discharged to a nursing home (intervention not suitable).
11. Patient transitions to late palliative phase during the hospitalisation (intervention not suitable).
12. Patient is transferred to a non-study ward and is discharged from there (hindering intervention delivery).
13. The patient dies during the course of the hospital stay (hindering intervention delivery).
14. No medication changes that last post-discharge during the hospitalisation (intervention not suitable).
15. The duration of stay on the study ward is less than 48 working hours (excluding time from 4:00 PM before weekends/public holiday to 8:00 AM the day after a weekend/public holiday) (hindering intervention delivery).

EHR = electronic health records

Intervention development

The intervention aims to improve medication communication during the discharge process for older patients. It was designed by a multidisciplinary team comprising researchers with backgrounds in social science, pharmacy, medicine, and nursing. Several team members also work professionally as healthcare practitioners in clinical settings, contributing practical insights from ongoing patient care. In addition, the team included two public representatives, ensuring that the perspectives of patients and informal caregivers were meaningfully integrated. The design built on findings from previous research conducted by our group [12,19,22]. The inclusion rate, as well as the feasibility of selected intervention components and outcome measures, were tested in unpublished pilot studies conducted at geriatric and surgical wards at Uppsala University Hospital, Sweden. These studies involved a total of 106 patients between September 2023 and May 2024 (Nordin J, Berlin K, Sabouni Y, du Thinh C, *et al.*: Facilitating patient empowerment at hospital discharge: A pilot study testing the feasibility of the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

181 IMPACT-care intervention, unpublished). Based on the results of these pilot studies, the intervention
182 and study design were refined before advancing to the main trial.

183 **Control period (preintervention)**

184 During the control period, care as usual will be provided at the study wards. Clinical pharmacists are
185 part of the care team at the wards and primarily assist with medication reviews at patient admission
186 and discharge but are not routinely involved in the discharge communication process. At hospital
187 admission, medication reconciliation is conducted by either a pharmacist or a physician. If needed, a
188 medication review is carried out by the physician, with or without support from a pharmacist. Any
189 changes to the patients' medication lists are made by wards physicians or nurse practitioners
190 (specialised nurses at the surgical wards). Oral medication-related communication with the patient
191 and/or informal caregiver, is typically handled by nurses, physicians, and pharmacists during patient
192 consultations. At discharge, hospitals are required to provide a discharge summary to the next
193 healthcare provider(s) and a discharge letter intended for the patient [34,35]. Both documents are
194 typically prepared by ward physicians and include details about the hospitalisation, medication
195 changes (along with the rationales for those), planned treatment duration, and follow-up plans. The
196 discharge letter, however, is expected to be written in layman's language. In some cases, these
197 discharge documents are written by a physician who has not met the patient prior to discharge.
198 Pharmacists sporadically assist in preparing these discharge documents, but not in a standardised
199 manner. Additionally, it is standard practice for ward physicians to send specific referrals to the next
200 healthcare provider(s), outlining follow-up requests related to medication changes. In addition, ward
201 physicians conduct an oral discharge consultation, during which the patient is informed about the
202 medication changes and follow-up plans before discharge.

203 While patients receive written information materials with practical information about the
204 wards and surgical procedures at admission, no materials specifically address medications or
205 medication communication at discharge. Inviting informal caregivers to participate in discharge

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

206 consultations and HCPs conducting follow-up calls after discharge occurs in selected cases but is not
207 routine practice.

208 **Implementation period: training of HCPs**

209 The training period will last approximately two months between the control and intervention
210 phases. During this period, HCPs - primarily physicians and pharmacists on the study wards - will
211 undergo training. Training of physicians will focus mainly on the importance of writing discharge
212 documentation and effectively utilising pharmacist support for this process. Training of pharmacists,
213 on the other hand, will focus on implementing the intervention components and understanding the
214 principles of person-centred medication communication at discharge. The training will be delivered
215 through multiple sessions led by the researchers, addressing how the study may impact daily ward
216 processes and how to integrate the intervention components into existing practices. To
217 accommodate newly hired HCPs during the intervention period, as well as those unable to attend
218 the live sessions, digital training materials will be developed and distributed to ensure that all
219 necessary training can be completed. Additionally, the pharmacists, who play a central role in
220 delivering the intervention components, will receive a standardised operation procedure document.
221 Other HCPs on the wards, excluding physicians and pharmacists, will be informed about the study
222 through meetings and information emails, which will outline how they may be affected by the study.
223 For training purposes, selected patients will undergo the intervention components without being
224 included in the study. Additionally, one of the researchers will also regularly visit the study wards to
225 support the HCPs in implementing the intervention components during this phase.

226 **Intervention period**

227 The intervention is designed to be implemented on hospital wards by clinical pharmacists who are
228 already part of the patient care team. Each of the study wards in our study has a full-time equivalent
229 clinical pharmacist present during weekday office hours, with a continuous presence established
230 over the past 15 years before the study began. The pharmacists involved have varying levels of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

231 experience, from limited to more extensive, some of whom have a one-year full-time postgraduate
232 MSc in clinical pharmacy. All relevant details about the completed intervention components and any
233 other actions taken by the pharmacist will be documented as usual in the patient's EHR. The
234 IMPACT-care intervention consists of the following four components (Figure 2):

235 1. *Information package provided to patients and/or informal caregivers.*

236 In our pre-study [22], it was identified that medication-related discharge communication is not
237 tailored to support patients' self-care needs post-discharge. Additionally, patients were unprepared
238 for medication-related consultations prior to discharge. To address these challenges, the research
239 team, inspired by a similar intervention component developed in the UK [36], designed an
240 information package consisting of a patient booklet (Supplementary material II) with input from
241 clinical pharmacists at Uppsala university hospital and a panel of public representatives.

242 The booklet is designed to inform, prepare, and engage patients and/or their informal
243 caregiver in medication communication at discharge and self-care after returning home. It is
244 organised into four sections: 1. Hospitalisation course, 2. Medications, 3. Discharge, and 4. Advice on
245 self-care. The first two sections feature a question prompt list [37], a set of discussion points
246 intended to guide conversations with HCPs and encourage patients to actively participate in their
247 care. The use of questions prompt list has been found to enhance patient participation in
248 medication-related communication [38,39]. The third section contains a checklist of essential points
249 for patients to review with HCPs to help confirm they have sufficient knowledge before leaving the
250 hospital. The final section provides practical advice on seeking medication and general healthcare
251 support after returning home.

252 Patients will receive the booklet in printed format at admission to the study ward and will be
253 accompanied by an oral consultation with one of the researchers who also practices clinically as a
254 pharmacist. During the consultation, the pharmacist will explain the content and guide the patient
255 on how to use the booklet effectively. The booklet will also be available online. If the patient wishes,
256 the pharmacist will provide the patient's informal caregiver access to the information package. This

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

257 can be done in person if the caregiver is present at the ward or remotely via phone, guiding them on
258 how to access the materials online.

259 2. *Preparation of medication-related discharge documentation.*

260 Incompleteness and poor quality of medication-related discharge communication from hospitals is a
261 common problem [40,41], making it difficult for subsequent HCPs to trust this information
262 [12,17,42]. Pharmacist involvement can significantly improve the completeness and quality of such
263 communication [40,41]. Consequently, in our study, the pharmacist will review relevant parts of the
264 patient's EHR and medication list prior to discharge to identify any lasting medication changes made
265 during the hospitalisation. The pharmacist will collaborate with the discharging physician to
266 reconcile follow-up plans for these changes. All medication changes, including reasons for the
267 adjustments (when known), planned treatment duration, follow-up plans, and the ward's phone
268 number for any post-discharge inquiries from the patient, will be documented in a standardised
269 manner in the EHR by the pharmacist. This documentation will form the basis for detailing
270 medication changes and follow-up plans in the patient's discharge letter and the discharge summary
271 intended for the next healthcare provider, both of which are written by a ward physician.

272 3. *Facilitation of discharge communication.*

273 To increase the likelihood that patients and their informal caregiver remember and use the booklet
274 provided to them during intervention component 1, the pharmacist will consult the patient as the
275 discharge date approaches. The consultation will include a review of the booklet's content and a
276 reminder to use it. If the patient wishes, the pharmacist will also contact the patient's informal
277 caregiver, either by phone or face-to-face, depending on the situation, to review the booklet and
278 remind them to use it.

279 Informal caregivers are considered as valuable support in helping patients recall information
280 and manage self-care after returning home [12]. However, they are often involved in a limited way in
281 medication-related discharge communication by HCPs [22,43]. To address this gap, the pharmacist in
282 our study will arrange for an informal caregiver to attend the discharge consultation with the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

physician, if the patient so wishes. The pharmacist will contact the informal caregiver by phone once the discharge date is confirmed - no later than the morning of discharge - and invite them to participate in the consultation. Participation can be in person, by phone, or via video call depending on their availability. The pharmacist will then inform the discharging physician that the patient has requested their informal caregiver’s involvement in the discharge consultation.

4. *Follow-up call to patients or their informal caregiver.*

The timing of medication-related discharge communication often occurs at a suboptimal moment for patients, making it difficult for them to retain and recall the information after returning home [22]. Incorporating intervention components both during hospitalisation and after discharge can help support medication continuity in older patients and bridge transitions [44]. Telephone follow-ups, in particular, have shown promise in enhancing this support [44]. Therefore, in our study, patients or their informal caregiver (based on the patient’s preference) will be offered a follow-up call with a clinical pharmacist post-discharge. If requested, the appointment for this call will be scheduled in consultation with the patient/informal caregiver, between 3-7 days after discharge, depending on the patient’s availability. The pharmacist will then contact the patient/informal caregiver at the agreed time. During the call, the pharmacist will start by addressing any questions the patient/informal caregiver may have, providing direct answers or referring inquiries to the appropriate HCP as needed. Following this, the pharmacist will review the medication-related discharge information, focusing on the updated medication list and details outlined in the discharge letter, including medication changes, reasons for the adjustments, planned treatment duration, and follow-up plans. Additionally, the pharmacist will remind the patient of the advice on when and how to seek care, as presented in the booklet provided during intervention component 1.

Outcomes

All outcomes will be assessed for participants from both the control and the intervention group (Table 2).

Primary outcome

The improvement in the quality of medication-related discharge documentation will be the primary outcome, assessed using the average score from the Complete Medication Documentation at Discharge Measure (CMDD-M) (Supplementary material III) [45]. This point-based instrument, ranging from 0 to 9 points, is based on Swedish legislation [35] outlining the requirements for written medication-related discharge documentation. The CMDD-M comprises five items, each scored from 0-1 or 0-2 points depending on the criteria. It evaluates the completeness and quality of medication-related discharge documents for individual hospital discharges, including the patient's discharge letter, the discharge summary intended for the next healthcare provider, and the presence of a follow-up request to bridge the gaps post-discharge. Improving the quality of discharge documentation is critical for ensuring continuity of care and patient safety during transitions of care [17]. Poor-quality documentation has been associated with medication errors [11], non-adherence [46], and avoidable need for medical care after discharge [47,48]. By focusing the primary outcome on this domain, the trial aims to address an important gap in care that impacts patient outcomes.

Secondary outcomes

- The proportion of patients with complete medication-related discharge documentation. This will be assessed using the CMDD-M to determine the prevalence of patients achieving the maximum score of 9 points.
- Improvement in patients' perceptions of knowledge and involvement in discharge medication communication, and their sense of security in post-discharge medication management. This will be assessed by the average score by the Patient Involvement in Medication Communication at Hospital discharge Questionnaire (PIMCH-Q) (Supplementary material IV). It consists of eight statements rated on a four-point Likert scale. It is designed with three dimensions: perception of knowledge, involvement, and sense of security, and aims to measure patients' perceived involvement in medication communication during hospitalisation and their sense of security in managing medications after discharge. The questionnaire will be sent to patients one week post-discharge.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Adherence to medication changes made during hospitalisation that persist post-discharge. This will be assessed by measuring the number of instances of non-adherence. Non-adherence to a medication change is defined as follows:
 - a. New or modified medications: A medication initiated or modified during hospitalisation (i.e., changes in strength, dose, or formulation) that is not dispensed from a community pharmacy within 14 days post-discharge. This applies regardless of whether the reason is a missing prescription or the patient not filling the prescription. Changes in strength or dose are included only when they create a safety risk for the patient if the previous prescription is used (e.g., reducing the dose of a tablet from 10 mg once daily to 2.5 mg once daily, which would require the patient to split the same tablet twice to get the correct dose, a practice considered unsafe).
 - b. Discontinued medications: A medication discontinued during hospitalisation (or with altered strength or formulation) that is erroneously dispensed using a previous prescription within 120 days post-discharge.

The rationale for collecting data up to 120 days post-discharge is based on standard pharmacy practices in Sweden, where medications are typically dispensed for a 90-day (three-month) supply at a time. Patients may have leftover supplies of discontinued medications at home and continue using them. However, if these medications are not refilled at a pharmacy within 120 days, the patient is considered adherent to the discontinuation.
- The proportion of patients who are fully adherent to the medication changes made during hospitalisation that persist post-discharge. This will be assessed by determining the prevalence of patients who have no instances of non-adherence as described above.
- Unplanned healthcare visits post-discharge. This will be assessed using the following outcome measures:

- The prevalence of patients with at least one unplanned hospital revisit (a composite measure of unplanned readmissions and emergency department visits) at 7, 30, and 90 days post-discharge.
- The prevalence of patients with at least one unplanned readmission at 7, 30, and 90 days post-discharge.
- The prevalence of patients with at least one emergency department visit (not followed by admission) at 7, 30, and 90 days post-discharge.
- The time to the first unplanned hospital revisit within 90 days.
- The time to the first unplanned readmission within 90 days.
- The time to the first emergency department visit within 90 days.
- The prevalence of patients with at least one potentially medication-related hospital readmission at 7, 30, and 90 days post-discharge, assessed using the validated AT-HARM10 tool [49,50].

Table 2. Timeline and overview of the scheduled data collection for both the control and intervention group participants.

	Admission	Discharge	Follow-up				
Time points (day)	-1 ^a	0	7	14	30	90	120
Study inclusion							
Eligibility screening	x	x					
Informed consent	x						
Demographic data	x	x					
Outcome measures							
CMDD-M ^b		x					

PIMCH-Q ^γ			x				
Adherence to medication changes				x			x
Hospital revisits			x		x	x	
Hospital readmissions			x		x	x	
Emergency department visits			x		x	x	
Medication-related readmissions			x		x	x	

^α Time point at which the patient is admitted to the study ward.

^β CMDD-M, a point-based instrument using data from the patient’s electronic health records.

^γ PIMCH-Q, a questionnaire to patients measuring their perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management.

CMDD-M = complete medication documentation at discharge measure, PIMCH-Q = patient involvement in medication communication at hospital discharge questionnaire

Data collection

Screening of patients at the study wards will be performed by the researchers, who are employed by the hospital. This will be done using information from the EHR and, if any unclarities occur, through contact with the ward HCPs. The researchers will invite eligible patients to participate and patients willing to participate will be asked to sign informed consent (Supplementary material I). Data will be collected from all participants, regardless of their adherence to the intervention, provided they do not withdraw their consent to participate in the study. This approach ensures complete follow-up data for inclusion in the intention-to-treat (ITT) analysis. The data collection will proceed in several steps (Table 2) and will be conducted by researchers in the research team and trained research assistants. To ensure uniformity of data collection, standard operating procedures have been developed. Data will be pseudonymised and transferred to case report forms (CRFs) in an electronic data capture system, REDCap [51]. All data processing and analysis will be based on the data in these CRFs and will be shared and discussed in pseudonymised form. Any forms and electronic files that

395 reveal research data of an individual patient will be stored in a locked archive at the hospital
396 pharmacy. Access to the final trial dataset will be restricted to the members of the research team.

397 *Demographic data*

398 Demographic data collected from the EHR will include age, gender, renal function, admission and
399 discharge dates, medication treatment at admission and discharge, whether the patient has support
400 by automatic dose-dispensation of medications, disease diagnoses, primary diagnosis for admission,
401 home care support, whether the patient lives alone, and the number of emergency department
402 visits and hospital admissions in the past year. Information about patients' education level will be
403 gathered through the researchers asking the patients at inclusion.

404 *Completeness and quality of discharge documentation*

405 After patient discharge, the discharge letter, discharge summary, and referrals to next healthcare
406 providers for follow up will be extracted from the EHR for scoring according to CMDD-M
407 (Supplementary material III). The instrument was specifically developed to be used in clinical settings
408 in Sweden. Initial validation demonstrated that the instrument is feasible for use in our setting [45].
409 Inter-rater reliability was assessed using Cohen's weighted kappa with both linear (Kw linear) and
410 quadratic (Kw quadratic) weights. The Kw linear for the comparison between two clinical
411 pharmacists was 0.92, while the comparison between their consensus and a geriatrician yielded a Kw
412 linear of 0.64. Similarly, the Kw quadratic was 0.97 for the comparison between the pharmacists and
413 0.80 for the comparison between their consensus and the geriatrician. These findings indicate
414 moderate to almost perfect reliability between raters and suggest that the CMDD-M instrument
415 provides robust reliability in assessing the quality and completeness of medication-related discharge
416 documentation in older hospitalised patients [45]. The CMDD-M was selected as the primary outcome,
417 as it was deemed the most appropriate and feasible option. Although only component 2 (preparation of
418 medication-related discharge documentation) of the intervention is expected to have a direct effect on
419 this measure, components 1 (information package provided to patients) and 3 (facilitation of discharge
420 communication) are also expected to exert indirect effects on the CMDD-M score by encouraging

1
2
3 421 patients/informal caregivers to request the discharge documents to which they are entitled and to ask
4
5 422 more questions about their medications. This, in turn, is anticipated to prompt physicians to provide
6
7 423 more explicit information in the documentation. Several alternative outcomes were considered but found
8
9 424 to be less suitable, e.g. unplanned hospital revisits would require an unfeasibly large sample size; the
10
11 425 PIMCH-Q lacks complete validation; and measuring adherence to medication changes raised concerns
12
13
14 426 about precision. These outcomes were therefore designated as secondary. Given its design and focus on
15
16 427 aspects directly relevant to our intervention, we anticipate it to effectively capture meaningful
17
18 428 changes within our study sample, even though the responsiveness of the CMDD-M to changes in the
19
20 429 completeness and quality of discharge documentation in response to an intervention has not yet
21
22
23 430 been evaluated. To ensure objectivity, the assessment using the CMDD-M will be conducted by the
24
25 431 researchers in a blinded manner. Data extracted from the EHR will be masked to prevent assessors
26
27 432 from linking patients to specific time periods, ensuring they remain unaware whether the patient
28
29 433 belongs to the control or intervention group.

31
32 434 *Patients' experience*

33
34 435 The PIMCH-Q will be sent to patients by mail or email, depending on their preferences, one week
35
36 436 after the discharge date (Supplementary material IV). The patients are asked to answer the
37
38 437 questionnaire as soon as possible. If no response is received within 10 days, the research team will
39
40 438 follow-up with a reminder via email or phone. During the reminder call, patients will also be offered
41
42 439 the option to respond by phone if preferred. The PIMCH-Q was selected for this study because, to
43
44 440 the best of our knowledge, no existing instrument adequately captures medication-related patient
45
46 441 experiences during hospital discharge. While its responsiveness has not yet been validated, the tool
47
48 442 was specifically designed to assess patient involvement in medication communication and
49
50 443 confidence in medication management post-discharge, which are core aspects of this study. Despite
51
52 444 the need for further validation, the PIMCH-Q remains the most suitable tool for achieving our study
53
54 445 objectives.

55
56 446 *Adherence to medication changes*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

447 Data about the lasting medication changes made and prescribed during hospitalisation will be
448 gathered from the EHR. Information on medications dispensed from pharmacies for each patient
449 120 days post-discharge will be obtained from the Swedish National Board of Health and Welfare's
450 national prescribed drug register. This register contains data on all medications dispensed from
451 community pharmacies in Sweden on a patient level. The extracted data will include the medication
452 name, the anatomical therapeutic chemical code, strength, prescribed quantity, collected quantity,
453 prescription date, collection date, prescriber's profession, and workplace. The assessment of the
454 number of instances of non-adherence will be conducted by the researchers.

455 *Healthcare Utilisation*

456 Unplanned hospital revisits, readmissions, emergency department visits, and time to these hospital
457 revisits within 90 days will be extracted from the EHR. The assessment whether the hospital
458 readmissions were potentially medication-related will be conducted retrospectively and blinded,
459 using the AT-HARM10 tool [49] through information from the EHR. The assessment will be
460 conducted by one clinical pharmacist and one physician who are not otherwise involved in the study.
461 Initially, they will independently evaluate each case, followed by a discussion to reach consensus on
462 cases where their initial assessment (e.g., whether a readmission is potentially medication-related)
463 differed.

464 **Process evaluation**

465 A mixed-method approach, combining both quantitative and qualitative methods, will be used for a
466 process evaluation to assess adherence to the study protocol and explore the implementation of the
467 intervention. The evaluation will be guided by the framework for process evaluation developed by
468 the UK Medical Research Council [52].

469 *Quantitative Process Evaluation*

470 The quantitative process evaluation will include all patients in the study to gain insight into the
471 extent of intervention implementation, the degree to which some intervention components may

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

already be in place during the control period, and adherence to the study protocol. The following data will be collected from the EHR:

- The proportion of control and intervention patients who received a discharge letter.
- The proportion of control and intervention patients for whom the clinical pharmacist prepared a medication discharge documentation.
- The proportion of intervention patients who received the information package.
- The proportion of control and intervention patients for whom the physician used the medication discharge documentation prepared by the pharmacist. This is measured by manually comparing the content of the prepared medication discharge documentation by the pharmacist with the actual medication summary in the discharge letter and final note written by the physician.
- The proportion of intervention patients who are reminded by the pharmacist to review the information package.
- The proportion of intervention patients who wish to have an informal caregiver present at the discharge consultation, and the proportion of those cases where the pharmacists contacts the informal caregiver to be present.
- The proportion of intervention patients who wish to have a follow-up call with a pharmacist after discharge, received the follow-up call, and whether it led to any pharmacist intervention, including details of the intervention.

Additional data collection methods:

- The proportion of all employed physicians and clinical pharmacists at the study wards who attend the training sessions. All HCPs attending the training sessions will be registered by the researchers. Data on HCPs who complete digital training sessions will be extracted from the digital training platform.
- The response rate of PIMCH-Q, along with the distribution method (paper, telephone, or digital). This will be extracted from REDCap.

- The proportion of control and intervention patients who recall having a discharge consultation, whether they wished to have an informal caregiver present, whether an informal caregiver was actually present, their desire for a follow-up call, and whether they received one. For control patients, these questions aim to determine the extent to which intervention components are performed as part of standard care. Additionally, for intervention patients, the proportion of patients who recall receiving the information package (intervention component 1) and their perception of it will be asked. These questions will be sent to patients alongside the PIMCH-Q.
- The amount of time used by pharmacists to deliver each component of the intervention, as well as the overall intervention, will be measured in a subset of the sample.

Qualitative Process Evaluation

Regular meetings with the pharmacists delivering the intervention will be scheduled during the intervention period to discuss and address implementation barriers that could be resolved to support successful implementation.

At the conclusion of the intervention phase, a qualitative process evaluation will be conducted with HCPs and patients. This will involve semi-structured interviews and focus groups with HCPs, specifically physicians and pharmacists from the study wards, who were actively involved in delivering the intervention, to explore their experiences and perceptions of its implementation. Semi-structured interviews will also be conducted with patients, and when applicable their informal caregiver, who received components of the intervention. This qualitative component will offer insights into how patients perceived the intervention. Patient interviews will be conducted either shortly before or within one week after discharge. A purposeful sampling approach will be adopted to obtain maximum variation. For HCP focus groups and interviews, variation will be sought in terms of sex, working experience, and study ward [53]. The same approach will be applied for patient interviews but this time to capture heterogeneity in age, sex, and health complexity. The concept of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

information power will guide the decision of sample size [54]. All interviews and focus groups will be audio-recorded and transcribed verbatim. The data will be analysed thematically [55].

Sample size calculation

The sample size calculation is based on the primary outcome, which is the quality of medication-related discharge documentation measured using the CMDD-M. The intervention will be deemed successful if the average score is significantly higher in the intervention group compared to the control group. For the calculation, we assumed an evenly distributed sample between the two groups and set the target difference in CMDD-M scores at one point. This conservative target was chosen as it represents the smallest measurable step in the instrument. In practice, a one-point difference may indicate the inclusion of medication changes in the discharge letter or discharge summary. Such an improvement reflects a critical enhancement in quality, with important implications for patient safety and continuity of care. Data from the pilot studies indicated that the baseline value for CMDD-M was 3.9 (SD 2.6) (Nordin J, Berlin K, Sabouni Y, du Thinh C, *et al.*: Facilitating patient empowerment at hospital discharge: A pilot study testing the feasibility of the IMPACT-care intervention, unpublished). Due to the maximum score limit in CMDD-M, the variance in scores is expected to differ between the control and intervention periods. This difference arises as scores may cluster near the upper limit, particularly in the intervention period where improved performance is anticipated, potentially leading to reduced variability compared to the control period. A two-sided t-test with Welch's correction for degrees of freedom (to account for the variance difference between groups) was used. A power of 0.8 was considered sufficient to detect an increase, with a 5% two-sided significance level. Based on these assumptions, a sample size of 115 patients per group, for a total of 230 patients, is required.

Additionally, a permutation test using the Mann-Whitney U-test was performed to assess the robustness of the t-test, yielding similar results.

Statistical analysis

A full statistical analysis plan (SAP) will be finalised prior to any analyses. Statisticians from the Uppsala Clinical Research Center (UCR) will oversee the statistical analyses. The primary analysis will follow the ITT principle, including all included patients in their assigned groups, regardless of protocol adherence. Additional analyses will include per-protocol (PP) analyses, i.e. excluding patients with protocol violations.

Descriptive analyses of the study population will be performed, with continuous data presented as mean $\pm$ standard deviation (SD) for normally distributed variables or as median and range for non-normally distributed variables. Categorical variables will be reported as frequencies and percentages. All outcomes will be summarised by study group, overall and by ward, descriptively. Comparative statistics between study groups will be conducted, with all statistical tests being two-sided and a p-value less than 0.05 considered statistically significant.

Models for analysing primary and secondary outcomes will include both unadjusted and fully adjusted analyses. Adjustments will account for age, gender, education level, ward type (geriatric or surgical), number of medication changes persisting post-discharge, number of medications at discharge, support by automatic dose-dispensation of medications, and duration of hospitalisation. Effect estimates, including odds ratios, hazard ratios, and rate ratios will be presented with 95 % CI and p-values.

Primary outcome analysis

Linear regression models with robust standard errors will be used to estimate the effect of the treatment groups on the CMDD-M score. The results will be reported as effect estimates. A sensitivity analysis of the primary outcome will be performed using a permutation-based Wilcoxon non-parametric test.

Secondary outcome analysis

Logistic regression will be used to analyse the prevalence of patients achieving the maximum score (9 points) on the CMDD-M, with results presented as odds ratios. The PIMCH-Q score will be analysed using linear regression models, evaluating the three dimensions both separately and in

total. Differences in the number of instances of non-adherence to medication changes persisting post-discharge will be assessed using quasi-Poisson regression models, with results reported as rate ratios. Logistic regression models will be used to analyse the prevalence of patients who are fully adherent to medication changes persisting post-discharge, with results reported as odds ratio.

The difference in the prevalence of patients with unplanned hospital revisits, unplanned readmissions, emergency department visits and medication-related readmissions at 7, 30, and 90 days post-discharge will be compared with logistic regression models, with results presented as odds ratios. Time to first unplanned hospital revisit, time to first unplanned readmission, and time to first emergency department visit will be analysed using Cox proportional hazards models. Patients who do not experience the event by the end of the study period or are lost to follow-up will be censored at their last known follow-up time, while patients who die before experiencing the event will be censored at the time of death. Results will be reported as hazard ratios.

Exploratory analyses

To analyse data collected at multiple regular intervals before and after the intervention, an ITS-analysis will be performed. A linear regression model will be estimated as follows:

$$Y=b_0+b_1T+b_2I+e$$

Where:

Y: Outcome variable (CMDD-M score, prevalence of patients achieving the maximum score on CMDD-M, PIMCH-Q score, or the number of non-adherence instances to medication changes persisting post-discharge)

b_0 : Intercept, representing the expected value of the outcome variable (Y) at baseline (T = 0 and I = 0).

b_1 : Time effect, indicating the change of the outcome variable (Y) for each day passed, regardless of the intervention.

T: Time in days passed from the start of the study, capturing natural changes in the outcome over time.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

600 b_2 : Intervention effect, representing the difference in the outcome variable (Y) between pre-
601 intervention (I = 0) and post-intervention (I = 1) periods, after accounting for time trends.
602 I: Dummy variable indicating whether the observation was collected before (0) or after (1)
603 intervention, enabling comparison outcomes before and after the intervention.
604 e: Error term, capturing random noise or unexplained variation in the outcome variable (Y).

605 This model will allow us to investigate whether there is an immediate effect following the
606 intervention. Results will be presented as regression estimates with 95% CI and p-values. This
607 analysis will be conducted for the following outcomes: CMDD-M score, prevalence of patients
608 achieving the maximum score on CMDD-M, PIMCH-Q score (the three dimensions separately and
609 total score), the number of non-adherence instances to medication changes persisting post-
610 discharge, and prevalence of patients who are fully adherent to medication changes.

611 *Process evaluation*

612 Quantitative data from the process evaluation will be presented with descriptive statistics by study
613 group and in total. No formal statistical tests will be performed.

614 **Public and patient involvement**

615 Two public representatives were involved in our research team throughout the intervention
616 development process: CB, who holds political duties advocating for patients, and UE, who serves as
617 the chairperson of an association for relatives of older patients. Both actively contributed to the
618 design and development of the intervention by attending research meetings and participating in
619 decision-making. Additionally, we engaged an advisory board comprising five public representatives,
620 all of whom are either members of senior associations or have experience as patients receiving
621 hospital care. This panel reviewed and provided suggestions to improve the wording of the consent
622 form for study inclusion and the PIMCH-Q sent to patients. They also played a key role in developing
623 the information package for intervention component 1, offering feedback on its design and content.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

This study involves human subjects and the handling of sensitive personal health data. Although, there is a risk associated with collecting sensitive patient data, we will minimise these risks by adhering to the General Data Protection Regulation (GDPR) [56], and the Declaration of Helsinki [57]. All participants will provide written informed consent before participation (Supplementary material I). The study has been approved by the Ethical Review Authority in Sweden (registration no. 2023-03518-01 and 2024-04079-02).

The aim of this intervention study is to evaluate whether a novel approach to medication-related discharge communication can improve patient care. The comparator chosen for this study is the current standard discharge process (care as usual), selected because it reflects the routine practices patients experience in the study settings and provides a relevant baseline for evaluating the intervention's impact. During the intervention period, in addition to the usual care, the intervention focuses on enhancing the quality of medication-related communication at discharge, involving patients and/or caregivers in discussions with HCPs, and offering a follow-up call after discharge to reinforce information retention. During the clinical pharmacists' follow-up phone calls with patients in the intervention group, new issues may be identified that need attention. If the pharmacist making the call is not the appropriate person to handle these issues, they will consult with another suitable HCP to ensure the problem is addressed.

We plan to publish the results of the main trial and any sub-studies in international peer-reviewed open-access journals, as well as present them at national and international conferences. The trial is expected to result in multiple published manuscripts, contribute to at least one PhD thesis, and support improved implementation of current Swedish regulations for medication-related discharge communication [35].

REFERENCES

1. United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects 2022: Summary of Results [Internet]. New York, NY; 2022. Available from:

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

- 650 <https://www.un.org/development/desa/pd/content/World-Population-Prospects-2022>
- 651 2. U.S. Centers for Disease Control and Prevention. Persons with hospital stays in the past year, by
652 selected characteristics: United States, selected years [Internet]. Atlanta; 2019. Available from:
653 <https://www.cdc.gov/nchs/data/hsr/2019/040-508.pdf>
- 654 3. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk
655 factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*. 2014
656 Dec 1;9:2079–86.
- 657 4. Hoel RW, Giddings Connolly RM, Takahashi PY. Polypharmacy Management in Older Patients.
658 *Mayo Clin Proc*. 2021 Jan;96(1):242–56.
- 659 5. Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of
660 the Recent Literatures. *Bull Emerg Trauma*. 2019 Oct;7(4):339–46.
- 661 6. Kempen TGH, Hedman AN, Hadziosmanovic N, Lindner KJ, Melhus H, Nielsen EI, Sulku J,
662 Gillespie U. Risk factors for and preventability of drug-related hospital revisits in older patients:
663 A post-hoc analysis of a randomized clinical trial. *Br J Clin Pharmacol*. 2023 May;89(5):1575–87.
- 664 7. El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt PMLA, Janssen MJA, Karapinar-
665 Çarkit F. Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic
666 Review. *J Am Geriatr Soc*. 03 2018;66(3):602–8.
- 667 8. World Health Organization. Transitions of Care: Technical Series on Safer Primary Care
668 [Internet]. Geneva; 2016. Available from:
669 <https://www.who.int/publications/i/item/9789241511599>
- 670 9. Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, Harchowal J, Raftery J,
671 Rajkumar C, on behalf of the PRIME study group. Incidence and cost of medication harm in
672 older adults following hospital discharge: a multicentre prospective study in the UK: Incidence
673 and cost of medication harm in older adults. *Br J Clin Pharmacol*. 2018 Aug;84(8):1789–97.
- 674 10. Spencer RA, Spencer SEF, Rodgers S, Campbell SM, Avery AJ. Processing of discharge summaries
675 in general practice: a retrospective record review. *Br J Gen Pract*. 2018 Aug;68(673):e576–85.
- 676 11. Caleres G, Modig S, Midlöv P, Chalmers J, Bondesson Å. Medication Discrepancies in Discharge
677 Summaries and Associated Risk Factors for Elderly Patients with Many Drugs. *Drugs Real World
678 Outcomes*. 2020 Mar;7(1):53–62.
- 679 12. Cam H, Wennlöf B, Gillespie U, Franzon K, Nielsen EI, Ling M, Lindner KJ, Kempen TGH,
680 Källemark Sporrang S. The complexities of communication at hospital discharge of older
681 patients: a qualitative study of healthcare professionals' views. *BMC Health Serv Res*. 2023 Nov
682 6;23(1):1211.
- 683 13. Knight DA, Thompson D, Mathie E, Dickinson A. “Seamless care? Just a list would have helped!”
684 Older people and their carer's experiences of support with medication on discharge home from
685 hospital. *Health Expect*. 2013 Sep;16(3):277–91.
- 686 14. Blozik E, Signorelli A, Reich O. How does hospitalization affect continuity of drug therapy: an
687 exploratory study. *Ther Clin Risk Manag*. 2016 Aug;12:1277–83.
- 688 15. Graabæk T, Terkildsen BG, Lauritsen KE, Almarsdóttir AB. Frequency of undocumented
689 medication discrepancies in discharge letters after hospitalization of older patients: a clinical

1
2
3 690 record review study. *Ther Adv Drug Saf.* 2019 Jun 16;10:2042098619858049.

4
5 691 16. Weetman K, Dale J, Spencer R, Scott E, Schnurr S. GP perspectives on hospital discharge letters:
6 692 an interview and focus group study. *BJGP Open* [Internet]. 2020 Jun 23;4(2). Available from:
7 693 <http://dx.doi.org/10.3399/bjgpopen20X101031>

8
9 694 17. Schwarz CM, Hoffmann M, Schwarz P, Kamolz LP, Brunner G, Sendlhofer G. A systematic
10 695 literature review and narrative synthesis on the risks of medical discharge letters for patients'
11 696 safety. *BMC Health Serv Res.* 2019 Mar 12;19(1):158.

12
13 697 18. Caleres G, Bondesson Å, Midlöv P, Modig S. Elderly at risk in care transitions When discharge
14 698 summaries are poorly transferred and used -a descriptive study. *BMC Health Serv Res.* 2018 Oct
15 699 11;18(1):770.

16
17 700 19. Cam H, Kempen TGH, Eriksson H, Abdulreda K, Franzon K, Gillespie U. Assessment of requests
18 701 for medication-related follow-up after hospital discharge, and the relation to unplanned
19 702 hospital revisits, in older patients: a multicentre retrospective chart review. *BMC Geriatr.* 2021
20 703 Nov 2;21(1):618.

21
22 704 20. Rognan SE, Källemark Sporrang S, Bengtsson K, Lie HB, Andersson Y, Mowé M, Mathiesen L.
23 705 Discharge processes and medicines communication from the patient perspective: A qualitative
24 706 study at an internal medicines ward in Norway. *Health Expect.* 2021 Jun;24(3):892–904.

25
26 707 21. Flink M, Ekstedt M. Planning for the Discharge, not for Patient Self-Management at Home - An
27 708 Observational and Interview Study of Hospital Discharge. *Int J Integr Care.* 2017 Nov 13;17(6):1.

28
29 709 22. Cam H, Franzon K, Sporrang SK, Kempen TGH, Bernsten C, Nielsen EI, Gustavsson L, Moosavi E,
30 710 Lindmark S, Ehlin U, Sjölander M, Lindner KJ, Gillespie U. "You're just thinking about going
31 711 home": Exploring person-centred medication communication with older patients at hospital
32 712 discharge. *Health Expect.* 2024 Oct 1;27(5):e70065.

33
34 713 23. Ozavci G, Bucknall T, Woodward-Kron R, Hughes C, Jorm C, Joseph K, Manias E. Knowledge and
35 714 Power Relations in Older Patients' Communication About Medications Across Transitions of
36 715 Care. *Qual Health Res.* 2021 Dec;31(14):2678–91.

37
38 716 24. Ozavci G, Bucknall T, Woodward-Kron R, Hughes C, Jorm C, Joseph K, Manias E. A systematic
39 717 review of older patients' experiences and perceptions of communication about managing
40 718 medication across transitions of care. *Res Social Adm Pharm.* 2021 Feb;17(2):273–91.

41
42 719 25. Kaplan RM, Frosch DL. Decision making in medicine and health care. *Annu Rev Clin Psychol.*
43 720 2005;1:525–56.

44
45 721 26. Maly RC, Bourque LB, Engelhardt RF. A randomized controlled trial of facilitating information
46 722 giving to patients with chronic medical conditions: effects on outcomes of care. *J Fam Pract.*
47 723 1999 May;48(5):356–63.

48
49 724 27. Pel-Littel RE, Snaterse M, Teppich NM, Buurman BM, van Etten-Jamaludin FS, van Weert JCM,
50 725 Minkman MM, Scholte Op Reimer WJM. Barriers and facilitators for shared decision making in
51 726 older patients with multiple chronic conditions: a systematic review. *BMC Geriatr.* 2021 Feb
52 727 6;21(1):112.

53
54 728 28. Bagge M, Norris P, Heydon S, Tordoff J. Older people's experiences of medicine changes on
55 729 leaving hospital. *Res Social Adm Pharm.* 2014 Sep;10(5):791–800.

56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

29. Eibergen L, Janssen MJA, Blom L, Karapinar-Çarkit F. Informational needs and recall of in-hospital medication changes of recently discharged patients. *Res Social Adm Pharm*. 2018 Feb;14(2):146–52.
30. The IMPACT-care project [Internet]. Akademiska sjukhuset [Uppsala University Hospital]. [cited 2024 Mar 26]. Available from: <https://www.akademiska.se/forskning-och-utbildning/forskningsrelaterat/har-bedriver-vi-forskning/impact-care/the-impact-care-project/>
31. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013 Feb 5;158(3):200–7.
32. Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for reporting outcomes in trial protocols: The SPIRIT-outcomes 2022 extension: The SPIRIT-outcomes 2022 extension. *JAMA*. 2022 Dec 20;328(23):2345–56.
33. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014 Mar 7;348:g1687.
34. Region Uppsala och samtliga kommuner i Uppsala län [Region Uppsala and the municipalities of Uppsala]. Samverkan vid utskrivning från slutenvård [Collaboration at hospital discharge] [Internet]. 2022. Available from: <https://publikdocplus.regionuppsala.se/Home/GetDocument?containerName=e0c73411-be4b-4fee-ac09-640f9e2c5d83&reference=DocPlusSTYR-17391&docId=DocPlusSTYR-17391>
35. Socialstyrelsen [National Board of Health and Welfare]. Socialstyrelsens föreskrifter och allmänna råd om ordination och hantering av läkemedel i hälso och sjukvården [The National Board of Health and Welfare's regulations and general guidelines on prescribing and handling of medications in health care] [Internet]. 2017. Available from: <https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/foreskrifter-och-allmanna-rad/konsoliderade-foreskrifter/201737-om-ordination-och-hantering-av-lakemedel-i-halso--och-sjukvarden/>
36. Lawton R, Murray J, Baxter R, Richardson G, Cockayne S, Baird K, Mandefield L, Brealey S, O'Hara J, Foy R, Sheard L, Cracknell A, Breckin E, Hewitt C, PACT research team. Evaluating an intervention to improve the safety and experience of transitions from hospital to home for older people (Your Care Needs You): a protocol for a cluster randomised controlled trial and process evaluation. *Trials*. 2023 Oct 14;24(1):671.
37. Sansoni JE, Grootemaat P, Duncan C. Question Prompt Lists in health consultations: A review. *Patient Educ Couns*. 2015 Jun 3;98(12):1454–64.
38. Svensberg K, Kaae S, Mottelson NB, Persson CL. Identifying critical elements in using Question Prompt Lists at the pharmacy counter to induce patient activation—using principles of conversation analysis. *Res Social Adm Pharm* [Internet]. 2024 Nov 4 [cited 2024 Nov 19]; Available from: <http://dx.doi.org/10.1016/j.sapharm.2024.10.008>
39. Ljungberg Persson C, Al-Nuaimi A, Esmaeili N, Svensberg K. Patients' attitudes towards using a

1
2
3 773 question prompt list in community pharmacies. *Patient Educ Couns*. 2023 Oct
4 774 1;115(107862):107862.
5
6 775 40. Tong EY, Roman CP, Mitra B, Yip GS, Gibbs H, Newnham HH, Smit DV, Galbraith K, Dooley MJ.
7 776 Reducing medication errors in hospital discharge summaries: a randomised controlled trial.
8 777 *Med J Aust*. 2017 Jan 16;206(1):36–9.
9
10 778 41. Elliott RA, Tan Y, Chan V, Richardson B, Tanner F, Dorevitch MI. Pharmacist-physician
11 779 collaboration to improve the accuracy of medication information in electronic medical
12 780 discharge summaries: Effectiveness and sustainability. *Pharmacy (Basel)*. 2019 Dec 30;8(1):2.
13
14 781 42. Uitvlugt EB, Siegert CEH, Janssen MJA, Nijpels G, Karapinar-Çarkit F. Completeness of
15 782 medication-related information in discharge letters and post-discharge general practitioner
16 783 overviews. *Int J Clin Pharm*. 2015 Dec;37(6):1206–12.
17
18 784 43. Hesselink G, Flink M, Olsson M, Barach P, Dudzik-Urbaniak E, Orrego C, Toccafondi G, Kalkman
19 785 C, Johnson JK, Schoonhoven L, Vernooij-Dassen M, Wollersheim H, European HANDOVER
20 786 Research Collaborative. Are patients discharged with care? A qualitative study of perceptions
21 787 and experiences of patients, family members and care providers. *BMJ Qual Saf*. 2012 Dec;21
22 788 Suppl 1:i39–49.
23
24 789 44. Tomlinson J, Cheong VL, Fylan B, Silcock J, Smith H, Karban K, Blenkinsopp A. Successful care
25 790 transitions for older people: a systematic review and meta-analysis of the effects of
26 791 interventions that support medication continuity. *Age Ageing*. 2020 Jul 1;49(4):558–69.
27
28 792 45. Bertilsson E, Östman V, Cam H, Franzon K, Gillespie U. Development and Validation of an
29 793 Instrument to Assess Quality and Completeness of Medication-Related Discharge
30 794 Documentation. *J Eval Clin Pract*. 2025 Feb 1;31(1):e70006.
31
32 795 46. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: Truth and
33 796 consequences. *Am J Med Sci*. 2016 Apr;351(4):387–99.
34
35 797 47. Midlöv P, Deierborg E, Holmdahl L, Höglund P, Eriksson T. Clinical outcomes from the use of
36 798 Medication Report when elderly patients are discharged from hospital. *Pharm World Sci*. 2008
37 799 Dec;30(6):840–5.
38
39 800 48. Gilmore-Bykovskiy AL, Kennelty KA, DuGoff E, Kind AJH. Hospital discharge documentation of a
40 801 designated clinician for follow-up care and 30-day outcomes in hip fracture and stroke patients
41 802 discharged to sub-acute care. *BMC Health Serv Res*. 2018 Feb 9;18(1):103.
42
43 803 49. Kempen TGH, Hedström M, Olsson H, Johansson A, Ottosson S, Al-Sammak Y, Gillespie U.
44 804 Assessment tool for hospital admissions related to medications: development and validation in
45 805 older patients. *Int J Clin Pharm*. 2019 Feb;41(1):198–206.
46
47 806 50. Kempen TGH, Hedman A, Gillespie U. Drug-related emergency department visits in older
48 807 patients: an applicability and reliability study of an existing assessment tool. *Int J Clin Pharm*.
49 808 2022 Aug;44(4):1078–82.
50
51 809 51. REDCap - Research Electronic Data Capture [Internet]. REDCap. [cited 2024 Feb 20]. Available
52 810 from: <https://www.project-redcap.org/>
53
54 811 52. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP,
55 812 McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for
56 813 developing and evaluating complex interventions: update of Medical Research Council

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 814 guidance. BMJ. 2021 Sep 30;374:n2061.
- 815 53. Patton MQ. Qualitative research & evaluation methods. 4th ed. Sage Publications Inc; 2015.
- 816 54. Malterud K, Siersma VD, Guassora AD. Sample Size in Qualitative Interview Studies: Guided by
817 Information Power. Qual Health Res. 2016 Nov;26(13):1753–60.
- 818 55. Malterud K. Systematic text condensation: a strategy for qualitative analysis. Scand J Public
819 Health. 2012 Dec;40(8):795–805.
- 820 56. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on
821 the protection of natural persons with regard to the processing of personal data and on the free
822 movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)
823 [Internet]. EUR-lex. [cited 2025 Feb 22]. Available from: [https://eur-lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32016R0679)
824 [content/EN/TXT/?uri=celex%3A32016R0679](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32016R0679)
- 825 57. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles
826 for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191–4.
- 827 58. CASRAI. CRediT - Contributor Roles Taxonomy [Internet]. 2019 [cited 2024 Mar 30]. Available
828 from: <https://credit.niso.org/>

Figure legends

- 831 ^α CMDD-M, a point-based instrument using data from the patient's electronic health records.
- 832 ^β PIMCH-Q, a questionnaire to patients measuring their perceptions of involvement in discharge medication
833 communication and their confidence in post-discharge medication management.
- 834 ^γ Data on lasting medication changes from the patient's electronic health records are compared to pharmacy
835 dispensing data collected 120 days post-discharge.
- 836 ^δ Unplanned hospital revisits and medication-related readmissions up to 90 days post-discharge.
- 837 CMDD-M = complete medication documentation at discharge measure, HCPs = healthcare professionals,
838 IMPACT-care = improved medication communication and patient involvement at care transitions, PIMCH-Q =
839 patient involvement in medication communication at hospital discharge questionnaire
- 840 **Figure 1.** Schematic overview of the study design.

- 841 * Based on the patient's preference, this may include their informal caregiver.
- 842 IMPACT-care = improved medication communication and patient involvement at care transitions
- 843 **Figure 2.** Overview of the IMPACT-care intervention, comprising four intervention components
844 implemented during patient hospitalisation and post-discharge.

DECLARATIONS

Acknowledgements

1
2
3 847 We thank the other members of the IMPACT-care research group and public representative group,
4
5 848 who are not listed as co-authors, for their contributions to the planning of this study protocol (in
6
7 849 alphabetical order): Emma Bertilsson, Agneta Darberg, Ellinor Eriksson, Nils Lannergård Probst, Mia
8
9
10 850 Ling, Karin Näslund-Westman, Gerd Waleij, and Björn Wennlöf. We also thank the patients who
11
12 851 participated in the pilot studies, as well as Karin Svensberg, the clinical pharmacists, public
13
14 852 representative panel, designers, and film crew who were involved in developing the information
15
16 853 package. We are grateful to Rebecca Lawton and Jenni Murray from the Yorkshire Quality and Safety
17
18 854 Research Group (<https://yqsr.org/>) for inspiring us to develop the information package and data
19
20 855 collection forms. Additionally, we acknowledge the students who contributed to various aspects of
21
22 856 preparations for this study protocol (in alphabetical order): Ludwig Bernhardt, Kristoffer Berlin, Mari
23
24 857 Bsada, Harleen Cheema, Melina Khashi, Maryam Mohamed, Jessica Nordin, Carolina Ravn, Yamen
25
26 858 Sabouni, and Cecilie du Thinh.
27
28
29 859 The authors used ChatGPT 4o (OpenAI) to assist in polishing the language during the writing process.
30
31 860 All content was reviewed and edited by the authors, who take full responsibility for the final
32
33 861 published article.
34
35
36
37 862 **Authors' contributions**
38
39 863 Contributions by each author according to the Contributor Roles Taxonomy (CRediT)[58]:
40
41 864 conceptualisation: all authors; funding acquisition: KF, TK, EN, KJL, CB, and UG; project
42
43 865 administration: HC, KF, VÖ, and UG; methodology: all authors; writing - original draft: HC; writing -
44
45 866 review & editing: all authors. All authors have read and agreed to the published version of the
46
47 867 manuscript. UG is the guarantor.
48
49
50 868 **Funding statement**
51
52
53 869 This work was supported by The Kamprad Foundation for Entrepreneurship, Research & Charity
54
55 870 [Familjen Kamprads stiftelse] grant number 20190109 and Regional Research Council Mid Sweden
56
57 871 [Sjukvårdsregionala forskningsrådet Mellansverige] grant number 967624. TK received postdoctoral
58
59 872 research funding from the Elisabeth and Alfred Ahlqvist foundation (Sweden). Open access funding


Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

873 was provided by Uppsala University. The funding bodies had no role in the design of the study, the
874 collection, analysis, interpretation of the data or the writing of the manuscript.

875 **Competing interests statement**


876 The authors declare no competing interests.

For peer review only



* Based on the patient’s preference, this may include their informal caregiver.
IMPACT-care = improved medication communication and patient involvement at care transitions
Figure 2. Overview of the IMPACT-care intervention, comprising four intervention components implemented during patient hospitalisation and post-discharge.

2681x539mm (72 x 72 DPI)



^α CMDD-M, a point-based instrument using data from the patient's electronic health records.

^β PIMCH-Q, a questionnaire to patients measuring their perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management.

^γ Data on lasting medication changes from the patient's electronic health records are compared to pharmacy dispensing data collected 120 days post-discharge.

^δ Unplanned hospital revisits and medication-related readmissions up to 90 days post-discharge.

CMDD-M = complete medication documentation at discharge measure, HCPs = healthcare professionals, IMPACT-care = improved medication communication and patient involvement at care transitions, PIMCH-Q = patient involvement in medication communication at hospital discharge questionnaire

Figure 1. Schematic overview of the study design.

1809x1148mm (72 x 72 DPI)

(Unofficial translation from documents in Swedish)

Consent form for patients in the control group

Information for research participants (patients) regarding participation in a research project in Region Uppsala

We would like to ask whether you are willing to participate in a research project. This document provides information about the project and what participation entails.

What is the project about, and why am I being asked to participate?

The aim of the project is to improve the quality of, and patient involvement in, medication communication when patients are discharged from hospital. The goal is to increase patients' sense of security and adherence to their medication treatment, as well as reduce the need for unplanned healthcare visits. We are focusing on patients aged 65 years or older, as many in this group take several medications. The project is carried out on the ward where you are currently receiving care, which is why you are being invited to participate.

The research sponsor for the project is Region Uppsala. The sponsor is the organisation responsible for the project. The study has been approved by the Swedish Ethical Review Authority (approval number: 2023-03518-01).

What does participation in the project involve?

The project consists of a control period, where care is provided according to standard routine, followed by an intervention period where additional measures are implemented to improve the quality of and patient involvement in medication communication. You are being invited to participate in the control group, which means you will receive care according to standard routines and be asked to complete a questionnaire approximately one week after discharge from hospital. It focuses on the medication information you received, and how involved and secure you felt after returning home. It takes approximately 5–10 minutes to complete and can be sent to you by post or email, depending on your preference.

What will happen with my data?

The project will collect and register information about your medication treatment, medications collected from the pharmacy, and any need for healthcare after discharge. This data will be obtained from your electronic health record and the Swedish National Board of Health and Welfare's medication register, and collection will continue for four months after discharge. Your questionnaire responses will also be recorded. Your name will be replaced with a code, and only researchers involved in the project will have access to the code key (the code linked to your personal identity number), which will be stored in a password-protected digital file within Region Uppsala's secure network. All data processing and presentation of results will be handled by the research team and Uppsala University in a

way that prevents identification of individual participants. For more information, please see the subheading *Handling of Personal Data* below.

Your participation is voluntary, and you may withdraw at any time without providing a reason. Choosing not to participate or withdrawing will not affect your future care or treatment. If you wish to withdraw, please contact the principal investigator (see below).

Possible risks and consequences of participation

You are covered by the patient insurance system, as with any healthcare service. We assess the risks of participating in this study to be low. Some participants may feel their privacy is affected, since information will be retrieved from electronic medical records and the prescribed drug register. Completing a questionnaire shortly after discharge may also feel burdensome.

How will I be informed of the results?

The study results will be published. If you wish, you may access the results once they are published in a scientific journal and in a more popular science format. You can request the results by contacting the principal investigator.

Principal investigator contact

Ulrika Gillespie, *address*, Phone: xxx, Email: xxx

Handling of personal data

All data will be handled in accordance with applicable confidentiality laws. Your information and responses will be stored in a database in a way that prevents unauthorised access. All physical data generated during the study will be stored for 10 years in a locked cabinet at Region Uppsala.

The data controller is Region Uppsala. Under the EU General Data Protection Regulation (GDPR), you have the right to access your data, correct any errors, request deletion, or restrict how your data is processed. To do so, contact Ulrika Gillespie (details above). The data protection officer can be reached at xxx or xxx. If you are dissatisfied with how your data is handled, you have the right to file a complaint with the Swedish Authority for Privacy Protection.

Consent to participate in the project

I have received verbal and/or written information about the study and have had the opportunity to ask questions. I will retain the written information.

I consent to participate in the project IMPACT-care: Improved medication communication and patient involvement at care transitions

☐ I would like to complete the questionnaires digitally.

Email: _____

Place & date	Signature
	Name
	Personal identity number

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Consent form for patients in the intervention group

Information for research participants (patients) regarding participation in a research project in Region Uppsala

We would like to ask whether you are willing to participate in a research project. This document provides information about the project and what participation entails.

What is the project about, and why am I being asked to participate?

The aim of the project is to improve the quality of, and patient involvement in, medication communication when patients are discharged from hospital. The goal is to increase patients' sense of security and adherence to their medication treatment, as well as reduce the need for unplanned healthcare visits. We are focusing on patients aged 65 years or older, as many in this group take several medications. The project is carried out on the ward where you are currently receiving care, which is why you are being invited to participate.

The research sponsor for the project is Region Uppsala. The sponsor is the organisation responsible for the project. The study has been approved by the Swedish Ethical Review Authority (approval number: 2023-03518-01).

What does participation in the project involve?

The project consists of a control period, where care is provided according to standard routine, followed by an intervention period where additional measures are implemented to improve the quality of and patient involvement in medication communication. You are being asked to participate in the latter phase of the project, during which the following elements will be added:

1. A clinical pharmacist on your ward will review your medications before you leave the hospital. The aim is to summarise changes made to your medication treatment during your hospital stay. This information will be documented in your medical record and support the physician responsible for providing written information (the medication list and discharge summary), as per routine, to you and your next healthcare provider before discharge.
2. You and your informal caregiver (if applicable) will receive an information brochure and access to an informational video while you are on the ward. These are designed to help you prepare for discharge and include tips on what to discuss with healthcare staff.
3. If you have an informal caregiver you would like to be informed about your medication changes, the pharmacist can help make arrangements for them to participate (in person or by phone/video call) in the conversation with the physician before you leave the hospital.
4. Before discharge, you will be offered a follow-up phone call with a pharmacist from the ward. This call will be scheduled for approximately one week after discharge. The purpose is to go through the written information (the discharge summary) you received and clarify any uncertainties.
5. About one week after your discharge, you will be asked to complete a questionnaire. It focuses on the medication information you received, and how involved and secure

you felt after returning home. It takes approximately 5–10 minutes to complete and can be sent to you by post or email, depending on your preference.

What will happen with my data?

The project will collect and register information about your medication treatment, medications collected from the pharmacy, and any need for healthcare after discharge. This data will be obtained from your electronic health record and the Swedish National Board of Health and Welfare’s medication register, and collection will continue for four months after discharge. Your questionnaire responses will also be recorded. Your name will be replaced with a code, and only researchers involved in the project will have access to the code key (the code linked to your personal identity number), which will be stored in a password-protected digital file within Region Uppsala’s secure network. All data processing and presentation of results will be handled by the research team and Uppsala University in a way that prevents identification of individual participants. For more information, please see the subheading *Handling of Personal Data* below.

Your participation is voluntary, and you may withdraw at any time without providing a reason. Choosing not to participate or withdrawing will not affect your future care or treatment. If you wish to withdraw, please contact the principal investigator (see below).

Possible risks and consequences of participation

You are covered by the patient insurance system, as with any healthcare service. We assess the risks of participating in this study to be low. Some participants may feel their privacy is affected, since information will be retrieved from electronic medical records and the prescribed drug register. Completing a questionnaire shortly after discharge may also feel burdensome.

A possible benefit is that we might identify issues that can be communicated to the hospital physician. Additionally, receiving a follow-up phone call one week after discharge may be helpful, as previous studies show that questions often arise after leaving hospital. These questions can be addressed directly during the call or forwarded to the responsible physician.

How will I be informed of the results?

The study results will be published. If you wish, you may access the results once they are published in a scientific journal and in a more popular science format. You can request the results by contacting the principal investigator.

Principal investigator contact

Ulrika Gillespie, *address*, Phone: xxx, Email: xxx

Handling of personal data

1
2
3 All data will be handled in accordance with applicable confidentiality laws. Your information
4 and responses will be stored in a database in a way that prevents unauthorised access. All
5 physical data generated during the study will be stored for 10 years in a locked cabinet at
6 Region Uppsala.
7
8

9 The data controller is Region Uppsala. Under the EU General Data Protection Regulation
10 (GDPR), you have the right to access your data, correct any errors, request deletion, or
11 restrict how your data is processed. To do so, contact Ulrika Gillespie (details above). The
12 data protection officer can be reached at xxx or xxx. If you are dissatisfied with how your
13 data is handled, you have the right to file a complaint with the Swedish Authority for Privacy
14 Protection.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Consent to participate in the project

I have received verbal and/or written information about the study and have had the opportunity to ask questions. I will retain the written information.

I consent to participate in the project IMPACT-care: Improved medication communication and patient involvement at care transitions

☐ I would like to complete the questionnaires digitally.

Email: _____

Place & date	Signature
	Name
	Personal identity number

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Your medications: from hospital to home

A support guide during your hospital stay to
help you prepare for going home



How to use this brochure

When staying in a hospital, many things happen, and it may be difficult to understand or feel comfortable with everything that takes place.

This information brochure is designed to support you and your relatives in gaining more knowledge about your care during your hospital stay and after you return home.

It is divided into four sections and includes information and suggested points to discuss with healthcare staff or your relatives.

You can mark the points you would like to discuss with the healthcare staff. You can also write down your own questions.

1 My hospital stay

2 My medications

3 Preparing to go home (discharge)

4 Advice for when I am home

Scan with a mobile camera for an informative film





My hospital stay

To be able to take care of your own health and manage your medication treatment when you return home, it helps if you have knowledge of what has happened during your hospital stay.

You can get this knowledge by:

- Talking to the healthcare staff about what is happening and asking if there is anything you are unsure about.
- Asking to be included in discussions about your care and medication treatment.

Points I would like to discuss

Mark the points you would like to discuss and/or write down other questions.

- What have I been treated for during my hospital stay?
- What is the plan for my care while I am still in the hospital?
- What is the plan for my care after I leave the hospital?
- What kind of help and support can I receive when I get home?
- How can my relatives help me?



My medications

It is common for medication changes to occur during a hospital stay, and it can be challenging to keep track of them.

You can ask healthcare staff about your medications. You can also discuss how to take them at home and whether you need any practice.

Points I would like to discuss

Mark the points you would like to discuss and/or write down other questions.

- What medications am I taking and why?
- How and when should I take my medications, and are there any special considerations?
- What changes were made to my medication during my hospital stay, and why?
- What effects can I expect from my new medications?
- What side effects should I be aware of?
- Where should I turn if I have questions or experience problems with my medications?
- Can I practice taking my medications (e.g., injections or inhalers) while in the hospital?
- What support is available if I need help with my medications at home?



Preparing to go home (discharge)

Discharge means it is time to leave the hospital, and there may be a lot of information for you and your relatives to discuss. This information is meant to help you understand what to expect when you return home and how to get help if needed.

Before leaving the hospital, you have the right to receive this information.

- **Discharge conversation:** A discussion with a doctor about what has happened during your hospital stay and the plan moving forward. It can be helpful if a relative is present.
- **Discharge summary with a medication report:** Written information about your hospital stay, changes made to your medications, and the next steps in your care. Read and keep the summary and show it to your relatives if needed.
- **Medication list:** A written list of the medications you should continue taking at home. Use this list and discard old ones.



Checklist before discharge

Review this checklist with healthcare staff to ensure everything is in order before leaving the hospital.

- ul style="list-style-type: none;">
- ☐ I know which symptoms to watch for.
- ☐ I know which medications to take when I get home and how to take them.
- ☐ I know where to go for prescription renewals.
- ☐ I know where to turn if I feel worse or have questions about my medications.
- ☐ I know how home care services or home nursing will assist me with my medications (if applicable).
- ☐ I know what follow-up care is planned for me.
- ☐ I have received my discharge summary.
- ☐ I have received my updated medication list.
- ☐ I have had a discharge conversation with a doctor.



Advice for when you are home



My medications

- If you have future questions about your medications, contact a pharmacy or your healthcare provider.
- If you forget which changes were made to your medications, check the discharge summary and medication list.
- The discharge summary and medication list from the hospital are also available in your medical records at 1177.se. You can also contact your healthcare center to obtain this information again.
- Always use the latest medication list provided by the hospital or your healthcare center. The list from a pharmacy may not include all recent changes, so do not rely on it.
- Unused medications should be returned to a pharmacy.
- Remember to renew your prescriptions in time.



Seek help if you feel worse

- Call 112 or go to the nearest emergency room if you fear you are experiencing something serious or life-threatening.
- You may still feel symptoms when you first return home. Contact your healthcare center or call 1177 if the symptoms persist, worsen, or if new symptoms arise.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Notes

Complete Medication Documentation at Discharge Measure (CMDD-M)

(Unofficial English version, translated from Swedish)

Item	Discharge letter (intended for the patient)	Points
1	The discharge letter includes a description of medication changes - 0 points: No - 1 point: Yes	0-1
2	All medication changes are explicitly* stated (<i>including duration/end date if time-limited</i>) - 0 points: No - 2 points: Yes	0 or 2
3	Reasons for all medication changes are stated - 2 points: The reason for all changes is included - 1 point: The reason for at least one change is included - 0 points: No reasons are stated ○ Automatically scored 0 points if item 2 is scored 0	0-2
Discharge summary (intended for the next healthcare provider)		
4	Information about medication treatment is included in the discharge summary (<i>sufficient if medications at discharge are listed, or if it is stated that medication changes have been made</i>) - 0 points: No - 1 point: Yes	0-1
5	All medication changes are stated - 2 points: All medication changes are explicitly* stated - 1 point: All changes are stated in a general** way - 0 points: At least one change is missing, or incorrectly stated ○ Automatically scored 0 points if item 4 is scored 0	0-2
Referral		
6	A referral is sent to the next healthcare provider - 0 points: No referral and medication changes were made - 1 point: Yes, or no referral needed (no medication changes made)	0-1
	Total	0-9

* Explicitly: For initiation and changes, state the medication name, strength, dose, dosage, and dosage form. For discontinuation state the medication name.

** General: For example, "Pain relief treatment initiated".

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Standard Operating Procedure (SOP) for using the CMDD-M

General Guidelines for Assessment

Identifying medication changes

- Medications at admission: Check the historical medication list from the day of admission. (Note: Admission could have been in another department.)
- Medications at discharge: Check the historical medication list from the day of discharge.
- Not considered a change:
 - o Medications added or removed from the medication list during a medication reconciliation at admission (these are corrections, not changes) as noted in the doctor's or pharmacist's note.
 - o Over-the-counter creams that can be purchased without prescription, regardless of the change made.
- Examples of how to assess combination preparations:
 - o If Ramipril Comp is discontinued and Ramipril is initiated, this counts as 1 discontinuation and 1 initiation.
 - o If two separate medications are switched to a combination preparation this counts as 2 discontinuations and 1 initiation.

Item-Specific Guidelines for Assessment

Items 2 and 5

- For initiation or changes to a medication, then name, strength, dose, dosage, and dosage form must be explicitly stated.
- For discontinuation, only the name must be stated.
- Medications prescribed solely for use during the hospital stay do not need to be included, such as intravenous antibiotics, insulin, infusion fluids, and similar medications.

Item 3

- The reason for a medication change may be acceptable if stated in general terms such as "for the heart", depending on the recipient.

Item 5

- Examples of general ways to state medication changes include:
 - o "Blood pressure medication reduced"
 - o "Pain relief treatment initiated"
- Simply stating "new medications prescribed" is not sufficient.

Patient Involvement in Medication Communication at Hospital discharge Questionnaire (PIMCH-Q)

(Unofficial English version, translated from Swedish)

Items	I strongly disagree	I disagree	I agree	I strongly agree	Don't know
While in hospital...					
1. I felt involved in decisions about my medication treatment that would continue after discharge (e.g., which changes would be made).					
2. I was offered the opportunity to have an informal caregiver present during the discharge consultation.					
3. I felt involved in decisions about the follow-up of my medication treatment.					
After returning home...					
4. I (and/or my informal caregiver) know what changes were made to my medication treatment in the hospital (e.g., new medications, medications I should no longer use, or changes in dosage).					
5. I (and/or my informal caregiver) know why my medication treatment was changed in the hospital (e.g., due to newly discovered atrial fibrillation or high blood pressure).					
6. I feel confident that I (and/or informal caregiver) can manage my medication treatment.					
7. I (and/or informal caregiver) know where to turn if I have questions about my medication treatment.					
8. I (and/or my relative) know how my medication treatment will be followed up.					